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 ABSTRACT 
There is a growing literature for cognitive late effects among childhood cancer survivors, 
yet little empirical information is known regarding specific neurocognitive outcomes of children 
who experience seizures while treated for acute lymphoblastic leukemia. This study examined 
prevalence of on-protocol seizures, seizure risk factors, and neurocognitive change in children 
with therapy-related seizures in comparison to the normative sample and a matched cohort of 
children without on-protocol seizures. Participants included children enrolled on the St. Jude 
frontline leukemia treatment protocol, Total Therapy 15 (TOTXV) - the first systematic 
investigation of intensified chemotherapy agents plus optimal intrathecal therapy without 
irradiation. Out of 498 children, 19 experienced therapy-related seizures. To increase the 
statistical power of comparisons, the 19 children were matched on relevant variables to two 
children without on-protocol seizures. Neuropsychological assessment and magnetic resonance 
imaging each occurred across three treatment time-points. Results revealed a 3.82% two-year 
incidence of seizures during TOTXV with over 50 percent of seizures during induction and 
consolidation phases. No demographic or clinical factors were predictive of seizures; although, a 
trend for standard/high treatment intensity was observed. When the neuropsychological 
performance of the seizure group was compared to normative scores, patterns of differences 
emerged and maintained across time-points for domains of attention, working memory, and 
processing speed significantly elevated for the seizure group. Similar patterns also emerged 
across time-points between the seizure group and the non-seizure cohort. At therapy completion, 
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 the seizure group performed significantly worse for attention and working memory tasks than the 
cohort, and these deficits persisted two years later with the addition of processing speed deficits 
and significantly worse intellectual functioning. Imaging findings indicated that children with 
therapy-related seizures experienced more significant early neurotoxicity (i.e., 
leukoencephalopathy) than non-seizure cohorts. Based on these preliminary findings, it appears 
that children who experience treatment-related seizures are at greater neurocognitive risk when 
compared to counterparts who do not. Findings point to a relationship between on-therapy 
seizures, leukoencephalopathy, and deficits in neuropsychological performance, specifically 
attention, working memory, and processing speed skills, which may lead to overall declines in 
intellectual functioning. Further research is needed to identify changes in neurocognitive status 
that indicate risk for long-term CNS effect in the hope of providing greater comprehension on 
how to earlier treat and prevent cognitive late effects. 
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ALL  Acute Lymphoblastic Leukemia 
CNS  Central Nervous System 
CRT  Cranial Radiation Therapy 
DEX  Dexamethasone 
HDMTX High Dose Methotrexate 
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INTRODUCTION 
The American Epilepsy Society (2006) defines a seizure as “the clinical manifestation of 
a hyperexcitable neuronal network, in which the electrical balance underlying normal neuronal 
activity is pathologically altered—excitation predominates over inhibition.” (p. 6). A diversity of 
medical health conditions engenders brain damage and abnormal electroencephalogram (EEG) 
activity which predispose patients to seizures. Seizures may also result as a side effect of 
treatment and medications. Several medical populations that are susceptible to seizures include 
those suffering with encephalitis, meningitis, Huntington’s disease, acquired immunodeficiency 
syndrome (AIDS), dementia, multiple sclerosis, stroke, traumatic brain injury, brain tumors, and 
other infections of the brain. One particular medical population that is at elevated risk for seizure 
experience due to the nature of treatment, and is the focus of this paper, is children treated for 
acute lymphoblastic leukemia (ALL).  
In order to understand the impact of seizure experience as an indicator of brain damage 
within this specific cancer population, it is helpful to first discuss seizure prevalence, etiology, 
classification, and clinical management within healthy child populations. It is also useful to 
examine the neuropsychological and neuroimaging correlates of seizures within healthy child 
populations. Next, this paper considers the neuropsychological consequences that occur within 
the context of leukemia treatment, including seizures. Comparisons between healthy children and 
children with cancer will aid in parsing out neuropsychological deficits related to leukemia 
treatment versus deficits related to seizure experience, with added appreciation for potential 
confounding factors or synergistic effects, when changes are observed.  
 1 
 Seizures in Healthy Children 
Prevalence 
 Seizures are among the most common, emergent pediatric neurologic problems 
(Friedman & Sharieff, 2006; Patel, Walsh, & Garg, n.d.), with approximately three to five 
percent of children in the United States experiencing a febrile seizure by age five (Reuter & 
Brownstein, 2002) and approximately 4 to 10 percent experiencing a seizure by age 16 (McAbee 
& Wark, 2000). Epidemiological research suggests that each year about 150,000 children in the 
United States experience a first unprovoked seizure, with 30,000 of those developing epilepsy 
(Hauser, 1994).  
Developing countries appear to be at two to three times higher risk for first onset seizure 
and epilepsy compared to incidence rates of Western, industrialized countries (Banerjee & 
Hauser, 2008). A review of studies suggests that males are at higher risk than females for 
unprovoked seizures even after controlling for risk factors such as head injury, as well as 
individuals from lower socioeconomic levels than those from high socioeconomic status even 
after controlling for race (Banerjee & Hauser, 2008). According to the International 
Classification of Epileptic Seizures, partial seizures appear the most common seizure type, 
accounting for just more than 50 percent of classified cases (Banerjee & Hauser, 2008; 
Commission on Classification and Terminology of the International League Against Epilepsy 
[ILAE], 1989). 
Etiology and Seizure Classification 
 Seizures have distinctive etiologies and are categorized by particular clinical descriptions 
and electroencephalographic wave patterns (Kaufman, 2001). Classification of seizure etiology 
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 as unprovoked or provoked is important in determining treatment options and prognosis (Chu-
Shore & Tseng, 2011). Causes of provoked seizures include head trauma; central nervous system 
(CNS) infections such as meningitis, encephalitis, and subdural empyema; metabolic 
abnormalities in glucose, sodium, or calcium levels; and cerebral structural abnormalities such as 
congenital malformations, stroke, or mass lesions (Chu-Shore & Tseng, 2011). Prenatal drug 
exposure and drug withdrawal must also be considered when identifying possible causes (Reuter 
& Brownstein, 2002). The most commonly identified cause of seizures in Western, industrialized 
countries is cerebrovascular disease, accounting for 12 percent of new onset cases; whereas, in 
South America, the most frequently identified cause is CNS infection (Banerjee & Hauser, 
2008). 
 Classification of seizure type and ruling out epileptogenic syndromes is also informative 
for treatment options and prognosis. The most frequently employed taxonomy is the ILAE’s 
International Classification of Epileptic Seizures, which was recently reorganized (Berg et al., 
2010). The two major seizure classifications include focal (previously partial), where network 
involvement is within just one hemisphere where abnormal activity is discretely localized or 
widely distributed, and generalized, where network involvement emerges within and engages 
bilateral hemispheres (Berg et al., 2010; Berg & Scheffer, 2011). Within the nomenclature of 
focal, it is important to categorize the seizure as either 1) without impairment in consciousness 
(simple partial) or 2) with impairment in consciousness, dyscognitive (complex partial). Simple 
partial seizures may be further characterized by one or more features: motoric, autonomic, or 
sensory/psychic aura aspects. Focal seizures typically last less than two minutes. It is important 
to note that focal seizures may evolve into bilateral, convulsive seizures. Generalized seizures 
include several categories: tonic-clonic (grand mal), absence (petit mal), tonic, clonic, atonic, 
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 and myoclonic. The tonic-clonic seizure typically lasts for three to five minutes. They are often 
preceded by an aura, followed by loss of consciousness with skeletal muscle tension (tonic) 
causing the person to fall if standing, followed by muscle convulsions that can range from 
twitching to violent, rapid movements of the tensed extremities (clonic), with often eyes rolled 
back or closed and tongue bruised by jaw contractions. Absence seizures are brief, usually lasting 
less than 20 seconds and involve impairment of consciousness with generalized spike-and-slow 
wave EEG discharges. Absence seizures are divided into two types: typical and atypical. Typical 
absence seizures are clinically identified as staring spells with impaired responsiveness or 
awareness and characterized by fast >2.5 Hz generalized spike-wave EEG discharges. Atypical 
absence seizures (<2.5 Hz spike and slow wave) may allow some responsiveness and be 
accompanied by eye blinking or twitching of the lips. Atonic seizures, or drop attacks, typically 
last less than 15 seconds and involve loss of muscle tone, causing the eyelids to suddenly drop as 
well as the body to drop if in standing position. Myoclonic seizures are very brief (less than two 
seconds) and involve rapid jerking or twitching of a muscle or muscle groups. 
Classification is based on a thorough history of clinical symptoms, description of the 
seizure event, and the identification of seizure antecedents, such as trauma, fever, or underlying 
medical conditions (Reuter & Brownstein, 2002; Williams & Sharp, 2000). While no routine 
laboratory procedures exist for first-onset seizures, a physical examination with vitals, 
supplemented by blood glucose levels is a good place to start (Reuter & Brownstein, 2002).  The 
electroencephalogram (EEG) is the preferred laboratory assessment as the presence of abnormal 
epileptiform discharges is diagnostic of seizure; however, a normal EEG does not rule out the 
possibility of seizures (Williams & Sharp, 2000). Ictal EEG recordings, while ideal, are rare to 
capture within the hospital setting and EEG recordings should be scheduled several days to 
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 weeks after the first seizure to avoid residual generalized slowing usually seen in the postictal 
phase (Reuter & Brownstein, 2002).  
Computed tomography or magnetic resonance imaging (CT or MRI) in the acute care 
setting is recommended when seizure duration is prolonged beyond 15 minutes, the postictal 
phase prevents clinical treatment, or high risk factors would indicate a positive scan of newly 
identified neuronal anomalies. Risk factors for positive imaging results include age 6 months or 
younger, first-onset focal neurological deficits, and high risk conditions such as a recent CSF 
shunt revision, closed head trauma, neurocutaneous disease, and malignancies (Reuter & 
Brownstein, 2002).  
Clinical Management of Seizures 
 The gold standard treatment for seizures and epilepsy is antiepileptic drugs or AEDs 
(Kaufman, 2001). Given seizures are clinical manifestations of a hyperexcitable neuronal 
network, the most successful anticonvulsants combat excitatory neuronal processes and enhance 
inhibitory neuronal processes (American Epilepsy Society, 2008). The most important CNS 
inhibitory neurotransmitter is gamma-aminobutyric-acid (GABA) and several anticonvulsants 
are known to enhance the inhibitory GABA system, such as clonazepam (Klonopin), tiagabine 
(Gabatril), pregabalin (Lyrica), and phenobarbital. The most important excitatory 
neurotransmitter is glutamate. Glutamate receptor antagonists as novel AEDs are appealing given 
their promising prevention of neuronal damage post-stroke and post-status epilepticus in addition 
to traditional seizure prevention (American Epilepsy Society, 2008). 
 Treatments for acute seizures, including status epilepticus, typically include 
benzodiazepines (e.g., diazepam, lorazepam, and midazolam), which disrupt and calm the whole 
system. Barbiturates (e.g., pentobarbital, phenobarbital, primidone, thiopental) are also 
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 commonly used. Both benzodiazepines and barbiturates have direct influence on the important 
inhibitory GABA system. 
While excessive AED dose concentration generally causes cognitive impairment 
including memory and attention difficulties (Kaufman, 2001), there is evidence that typical 
administration of anticonvulsants may have deleterious effects on cognitive outcomes. 
Management of seizures via AEDs is a matching game of sorts as the individual may be best 
treated by an AED other than the one with the best statistical cognitive-behavioral profile in 
controlled clinical studies (Devinsky, 1995). Phenytoin has been shown to impair memory and 
cognition, which resolves after drug withdrawal (Gallassi et al,, 1988). Two other drug 
withdrawal studies of children successfully treated for epilepsy with carbamazepine (CBZ), 
phenytoin (PHT), valproate (VPA) monotherapy revealed improved cognitive functioning for 
measures of psychomotor speed (Aldenkamp et al., 1993, Blennow et al., 1990). In one study, 
children who were seizure-free for a year withdrew from AEDs for three months with 
neuropsychological re-evaluation after complete withdrawal at three to four months later. 
Improvement was found on just one neuropsychological measure of psychomotor speed, and 
children prescribed PHT experienced greater cognitive impairment on measurements of mental 
and motor speed than those prescribed CBZ (Aldenkamp et al., 1993). In the other study, 
researchers found that withdrawal from AEDs improved performance on binary choice and 
visual search tasks, although these findings were similar to the healthy control group (Blennow 
et al., 1990). Of mention however is that children prescribed CBZ performed most similar to 
healthy children before and after drug withdrawal, whereas children prescribed PHT performed 
most poorly. A similar pre- and post-withdrawal poor performance pattern was noted for children 
prescribed VPA (Blennow et al., 1990).  
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 A recent randomized, double-blind, placebo-controlled study examined the impact of 
AED discontinuation on measures of attention, reaction time, and information processing speed 
in 150 patients without seizures for more than two years on monotherapy AEDs mostly 
consisting of CBZ and VPA (Hessen, Lossius, Reinvang, & Gjerstad, 2006). The main finding 
was that AED discontinuation significantly improved performance on tasks requiring complex 
cognitive processing under time pressure when compared to performance of the non-
discontinuation group. Attention and reaction time tasks were not significantly different between 
groups. Similar to Blennow and colleagues’ (1990) findings, when examining drug type, 
discontinuation of CBZ produced significant results parallel to the overall study outcome, 
whereas VPA discontinuation demonstrated a non-significant trend in the same direction (Hessen 
et al., 2006). In a randomized, double-blind study, verbal memory has also been shown to 
improve following CBZ and VPA discontinuation (Hessen, Lossius, & Gjerstad, 2011). 
Impact of Seizures on Neuropsychological Outcomes  
 Until the late 90s, research in the area of cognitive outcomes for children diagnosed with 
epilepsy focused mostly on overall intellectual functioning and achievement (Williams, Griebel, 
& Dykman, 1998). While some researchers asserted that intelligence for children with epilepsy 
followed the normal curve seen in the healthy child population, others reported intelligence 
findings skewed toward the low average range. Achievement abilities have generally been found 
to be disrupted within children diagnosed with epilepsy, regardless of seizure type or treatment. 
While some studies point to a hemisphere lateralization of deficits based on seizure type (i.e., 
right versus left temporal lobe epilepsy), others do not evidence hemispheric differences when 
examining verbal and performance abilities, personality, or school problems (Camfield et al., 
1984). 
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  The relationship between seizures and cognitive impairment may be an indirect one, 
where learning problems and disruptions in cognitive development are secondary to a general 
decreased alertness and inattention stemming from the seizure activity (Sturniolo & Galletti, 
1994). Regardless of causal mechanisms, cognitive impairment has been well established in 
children with epilepsy (Farwell, Dodrill, & Batzel, 1985; Williams & Sharp, 2000), appearing at 
seizure onset (Fastenau et al., 2009) and possibly even emerging before onset based on the 
transient cognitive impairment model, in which cognitive disruptions are indicated by 
epileptiform EEG discharges (Aldenkamp & Arends, 2004).  
Appreciating risk factors and specific causes for neurocognitive deficits is crucial in 
prompt intervention for common cognitive and academic difficulties. Given this, there has been a 
recent shift from measuring global cognitive abilities to measuring more specific cognitive 
abilities. Neuropsychological assessments often include performance measures of memory, 
attention, processing speed, language, fine motor skills, executive function, visual motor 
integration, and parental report of behavior.  
Healthy children with seizures experience adverse effects for specific cognitive 
outcomes, including decreased short-term memory, visual spatial difficulties, and poorer 
concentration, when compared to same-age peers (Blennow et al., 1990; Dam, 1990). The most 
consistent finding across studies in children with seizures is the disruption of attentional skills 
(Williams & Sharp, 2000). 
Fastenau and colleagues (2009) examined outcomes for four factors of 
neuropsychological performance (factor 1: attention/executive/construction; factor 2: language; 
factor 3: processing speed; factor 4: verbal memory and learning) and academic achievement for 
282 children with first onset seizure in comparison to a healthy sibling group (n=147). 
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 Neuropsychological deficit was operationalized as 1.3 SD below the healthy sibling norm on the 
4 factors, corresponding with the 10th percentile or upper range of borderline intellect. While 
there was no difference between groups in academic achievement, children with seizures 
performed worse on all measures of neuropsychological functioning when compared to healthy 
siblings, particularly for the factor of attention/executive/construction (Fastenau et al., 2009). 
Children with seizures also displayed significantly higher odds ratio for neuropsychological 
deficits in at least one neuropsychological domain, by important clinical risk factor than the 
sibling group (27.4 percent versus 18.2 percent, respectively, χ 2 p = .04), with nearly twice as 
many in the seizure group demonstrating deficits for factors of language, verbal memory and 
learning, and attention/construction/executive functioning, (13.9 percent versus 7.7 percent for 
each factor). The proportion for processing speed was somewhat narrower (13.5 versus 8.4). 
Antiepileptic drug (AED) use was related to neuropsychological deficiencies on all four factors. 
A second seizure, even in non-medicated children, was found to be related to deficits in 
attention/construction/executive functioning. The authors assert that this finding adds to the 
conceptualization of deleterious effects of seizures, which are not limited to children with 
frequent seizures, generalized symptomatic epilepsy, high AED usage, or extremely early onset 
(Fastenau et al., 2009). 
Newer research indicates that abnormalities in neuropsychological function, brain 
structures, and behavior are present even at, or near, the time of new seizure diagnosis (Hermann 
et al., 2012). Thorough clinical histories suggest that neurologic problems and behavioral 
difficulties even exist before the first seizure. Within the literature on seizures and epilepsy, the 
cause and development of neurobehavioral comorbidities (a broad term which includes cognitive 
status, psychiatric status, and social-adaptive behaviors) is covered by Hermann and colleagues 
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 (2012) in hope of providing greater knowledge and comprehension on how to treat and prevent 
these difficulties.  
Three items of evidence are provided by the authors in support of neurodevelopmental 
influence of seizures (Hermann et al., 2012). The first piece of evidence includes data revealing 
that individuals with earlier age at onset of recurrent seizures suffer more adverse consequences 
for cognitive function (Hermann et al., 2002; Kaaden & Helmstaedter, 2009). The second piece 
of evidence comes from 30-year-long or longer controlled community and population-based 
studies following those with childhood-onset epilepsy, showing that it effects essential quality of 
life factors including marriage, employment, income, social involvement, independent living, 
psychiatric condition, and other major lifespan outcomes, even in those with intact intelligence 
and those in remission without AED assistance (Hermann et al., 2012). Unfavorable lifespan 
outcomes have been found to be related to neurobehavioral comorbidities such as early history 
of psychiatric or cognitive/learning problems (e.g., Attention-Deficit/Hyperactivity Disorder, 
ADHD). The third and final piece of evidence includes population-based and clinical care center 
investigations of neurobehavioral comorbidities in children with epilepsy, which indicate 
reduced performance in overall cognitive abilities, language abilities, executive function, 
academics, mood, nonverbal reasoning, verbal memory, motor functioning, and psychosocial 
function (Hermann et al., 2012).  
It appears that a number of factors are related to these neuropsychological deficits, such 
as age at seizure onset, seizure frequency and recurring seizures, epilepsy type, length of illness, 
EEG results, and AED usage. There is some caution, however, in using these variables as sole 
predictors given their inconsistency across studies and findings of other factors influencing 
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 declines in neuropsychological performance, such as pre-existing neuropsychological 
impairment, learning difficulties, psychopathology, and family factors (Jones et al., 2010). 
Neuroimaging Correlates of Seizures  
 Although the neuroimaging findings among children with seizures are limited in 
comparison to the cognitive impact of seizures literature, it serves as a promising companion to 
understanding the neuropsychological consequence and sequelae of seizures. Childhood seizure 
onset has been shown to be related to reductions in whole brain volume among individuals with 
complicated febrile convulsion (Theodore et al., 2003), abnormal white and gray matter volumes 
(Hermann, 2002; Kaaden et al., 2011; Riley et al., 2010), altered volumes of the corpus callosum 
(Hermann et al., 2003; Weber et al., 2007), and disruptions in white matter connectivity among 
individuals with chronic partial epilepsy (Herman et al., 2003). 
Children with Acute Lymphoblastic Leukemia (ALL) 
Prevalence of ALL 
Leukemia is the most common type of childhood cancer, with acute lymphoblastic 
leukemia (ALL) accounting for three out of four cases of childhood leukemia. The American 
Cancer Society (2012) estimated approximately 6,050 new cases of ALL in the United States for 
2012. For reasons unknown, the incidence of ALL across race is notably higher in Caucasian 
children than in African American children, although highest in Hispanic children (National 
Cancer Institute, 2012). 
Treatment of ALL 
Survival rates. Survival rates for children with ALL have improved dramatically over 
the past several decades from less than 10 percent to nearly 90 percent (Pui et al., 2009). 
Increases in survivorship were initially related to prophylactic treatment of the CNS to reduce 
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 secondary malignancies, particularly once-standard cranial irradiation treatment. With the advent 
of chemotherapy, prophylactic treatment has improved in its specificity and sensitivity, and in 
turn, enhanced survival rates. Although survival has increased, 20 percent of treatment protocols 
still employ radiation, with radiation-related cognitive late effects observed in more than two-
thirds of survivors (Pui, 2004). Cognitive late effects are defined as neurocognitive deficits (e.g., 
executive function, memory, attention, processing speed) and learning difficulties observed at 
two to five years after treatment (National Cancer Institute, 2012). Therefore, great efforts have 
been made to intensify systemic and intrathecal chemotherapy in order to offset potential risks of 
removing cranial irradiation therapy from ALL treatment. 
A recent study including more than 21,000 children with ALL (more than half of the 
United States’ patients) that took part in the Children’s Oncology Group 1990 to 2005 clinical 
trials revealed a higher 5-year survival rate of 90.4 percent for children diagnosed between 2000 
and 2005 compared to 83.7 percent for those diagnosed from 1990 to 1994 (Hunger et al., 2012). 
Children aged 1 to 9 years are more likely to experience disease-free survival than infants and 
children aged 10 or older (Möricke et al., 2005; Schrappe et al., 2000; Smith et al., 1996). 
Although prognosis is favorable, childhood cancer survivors are still at risk for 
significant acute and long-term sequelae related to disease and treatment, with 60 percent 
experiencing at least one long-term treatment-related side effect (Fulbright et al., 2011; Kopp et 
al., 2012; Oeffinger & Hudson, 2004). There is increased focus on the effect of chemotherapy on 
psychosocial and quality of life issues, including neurobehavioral outcomes (Phipps et al., 2012). 
Most often studied indicators of neurotoxicity include global intellectual and academic 
performance, although there has been a recent focus on specific neurocognitive processes (Butler 
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 & Haser, 2006; Phipps et al., 2012). Research data on cognitive late effects of childhood 
leukemia support the conceptualization that it is a chronic illness in need of continued care for its 
expanding survivorship population (Phipps et al., 2012).  
Impact of Chemotherapy Alone on Cognitive Outcomes of ALL Survivors 
While the elimination of cranial radiation therapy (CRT) from leukemia treatment has 
reduced overall neuropsychological impairment in ALL survivors, neurocognitive problems 
(predominately working memory and attention deficits) still exist among the population in subtle 
yet significant ways that impact daily life (Ashford et al., 2010; Conklin et al., 2012). Reviews 
and meta-analyses of the neurocognitive effects of central nervous system (CNS-directed) 
chemotherapy in ALL survivors suggest an adverse impact on several domains of 
neuropsychological functioning (Anderson & Kunin-Batson, 2009; Buizer et al., 2005, 2009; 
Campbell et al., 2007; Moore, 2004, Nathan et al., 2007; National Cancer Institute, 2012; 
Peterson et al., 2008). Cognitive impairments include deficits in intellectual and academic 
functioning (particularly arithmetic skills), verbal and nonverbal memory, verbal comprehension, 
attention, processing speed, complex fine motor skills, visual-motor integration, visual-spatial 
skills, and facets of executive function (Brown et al., 1992; Halsey et al., 2011; Jansen et al., 
2008; Mennes et al., 2005; Moleski, 2000; Peterson et al., 2008). Risk factors that account for 
worse cognitive outcomes include younger age at diagnosis, female gender, greater time since 
treatment, and higher treatment intensity (Buizer et a., 2005; Buizer et al., 2009; Cohen & 
Duffner, 1991; Conklin et al., 2012; National Cancer Institute, 2012; Peterson et al., 2008; 
Phipps et al., 2012; von der Weid, 2003).  
Leukemia treatment specialists have made a case for refined measurement of cognitive 
deficits in particular neuropsychological functions, namely central processing skills, as they 
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 appear to account for overall intellectual and academic declines, as well as nearly 50 percent of 
age-related developmental improvements (Fry & Hale, 1996; Phipps et al., 2012). Central 
processing is a mid-level term that includes a subset of performance-based cognitive skills such 
as attention to stimuli, speed of processing information, recall of information, and other 
executive functions such as working memory, or holding information “online” (Phipps et al., 
2012). Meta-analyses have suggested that ALL survivors experience significant decrements in 
these areas (Campbell et al., 2007; Peterson et al., 2008).  
Of the central processing skills, deficits in processing speed and working memory skills 
appear particularly important in relation to the emergence of cognitive late effects. Of the two, 
working memory measurements seem most useful in detecting treatment-related change, as they 
are sensitive to cognitive declines even in non-irradiated, chemotherapy-only samples where 
treatment intensity is based on risk (e.g., low and standard/high). Increased chemotherapy dosing 
of intravenous methotrexate worsens cognitive deficits, specifically declines in attention, (Buizer 
et al., 2005) and attentional deficits in ALL survivors have been linked to smaller and abnormal 
cerebral white matter volumes (Ashford et al., 2010; Reddick et al., 2006).   
Central processing skills as a mediator in cognitive late effects of CNS-directed therapy 
is substantiated by the temporal-spatial sequence of neurobehavioral declines in relation to 
chemotherapy and temporal-spatial coherence between cognitive declines and decreased cerebral 
white matter volumes (Schatz et al., 2000). Ashford and colleagues (2010) also discovered that 
working memory performance scores, which identified cognitive deficits overlooked by 
estimated intelligence scores, predicted overall intelligence scores. Detecting performance 
declines in these specific, purported mediating neuropsychological processes (e.g., working 
memory, attention) adversely affected by chemotherapy is necessary to develop targeted, cost- 
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 and time-effective interventions. It will also assist in the discovery and confirmation of neural 
pathways hypothesized to be directly related to these neurobehavioral deficits (Phipps et al., 
2012). 
Impact of Chemotherapy on Behavioral and Psychological Functioning of ALL Survivors 
 Surprisingly, children with cancer cope relatively well, often reporting similar or even 
lower levels of psychological distress (e.g., depression and anxiety) than healthy peers (Phipps, 
2007). Reviews reveal that both self- and other-reports of psychological distress suggest lower 
levels of distress in cancer survivors, relative to children with other chronic illnesses (Eiser, Hill, 
& Vance, 2000; Lavigne & Faier-Routman, 1992; Noll et al., 1997; Patenaude & Kupst, 2005; 
Phipps & Srivastava, 1997).  
 The lack of maladjustment findings has created skepticism for some researchers who 
argue that traditional symptom measures are unable to portray difficulties unique and specific to 
the childhood cancer population. As a result, the past decade’s pediatric cancer coping research 
has focused on symptomatology of post-traumatic stress disorder (PTSD), particularly 
subclinical levels of post-traumatic stress symptoms (PTSS) given null findings of significant 
PTSD within the pediatric cancer population (Bruce, 2006). Yet significant differences in PTSS 
have not emerged in the few studies comparing pediatric cancer samples to healthy controls 
(Barakat et al., 1997; Schwartz & Drotar, 2006).  
Research conducted at St. Jude Children’s Research Hospital suggests that adaptive style 
plays a more prominent role than history of health condition in contributing to PTSS (Phipps, 
Jurbergs, & Long, 2009; Phipps, Larson, Long, & Rai, 2006). Adaptive style, or individual 
disposition to perceived threats, was measured by self-reported defensiveness and trait anxiety, 
allowing researchers to categorize children’s adaptive style into four groups: repressor, low 
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 anxiety, high anxiety, and defensive high anxious. Children categorized as low anxious or 
repressive adaptive style (low anxiety, high defensiveness) endorsed lower levels of PTSS than 
children categorized as high anxious. High anxious adaptive style was associated with a greater 
probability of arousal, avoidance, numbing, intrusive thoughts, and re-experiencing of events 
(Phipps et al., 2006). In a following study with an added healthy child control group, the adaptive 
style findings were replicated regardless of health condition and there was a lack of significant 
group differences for PTSS (Phipps et al., 2009). Relapse was the only cancer-related variable 
correlated with elevated PTSS. While children with cancer endorsed greater numbing and 
avoidance than healthy children, they also endorsed fewer intrusive thoughts and trauma re-
experience. Other research findings and reviews have also questioned the conceptualization of 
childhood cancer experience as a traumatic event, offering alternative conceptual models such as 
“psychosocial transition” (Cordova & Andrykowski, 2003; Deimling et al., 2002) and “post-
traumatic growth” (Barakat, Alderfer, & Kazak, 2006).  
Impact of Chemotherapy on Neuroimaging Outcomes 
While CRT with and without chemotherapy (primarily methotrexate) has been strongly 
linked to intracranial white matter changes, vascular damage, and other serious 
neuropsychological and neuroendocrine issues (Cohen & Duffner, 1991; Packer et al., 1987), 
chemotherapy alone has also been considered by some investigators to result in comparable 
neurocognitive side effects (Buizer et al., 2009). Consequences of chemotherapeutic drugs 
include brain atrophy, vascular injury, and white matter damage; the latter termed 
leukoencephalopathy or reversible acute methotrexate neurotoxicity (Anderson & Kunin-Batson, 
2009; Paakko et al., 2000; Reddick et al., 2006; Wilson et al., 1991). Leukoencephalopathy 
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 prevalence, measured by MRI, is as high as 86 percent after seven intravenous high-dose 
methotrexate (MTX) rounds, with a reduced 40 percent at treatment completion (Reddick et al, 
2005). If methotrexate neurotoxicity has not reversed at end of therapy, it is thought to resolve 
within a year or so after (Haykin et al., 2006; Wilson et al., 1991; Ziereisen et al., 2006). 
However, using single-photon emission computed tomography (SPECT), Paakko and colleagues 
(2000) discovered small brain perfusion defects at up to eight years post-treatment, which were 
missed by perfusion MRI.  
Younger aged children’s developing brains are more vulnerable to therapy-related 
neurotoxicity, evidenced by measured decreased cerebral white matter volumes and increased 
oxidative stress in the CNS post-treatment (Rajamani et al., 2000). Females appear to be 
particularly vulnerable to the effects of CNS-directed therapy as males’ neurodevelopmental 
experience involves greater white matter volume increases in childhood (Maytal et al., 1995). 
Biomarkers of oxidative stress include increased levels of brain specific proteins. Oxidized 
fractions of the most prevalent cerebrospinal fluid phospholipid called phosphatidylcholine (PC) 
measured after induction and consolidation phases of chemotherapy treatment predict executive 
function decline two years later (Caron et al., 2009).  
Impact of therapy medications. Leukemia chemotherapeutic agents commonly include 
methotrexate (MTX), cytosine arabinoside (Ara-C), L-asparaginase (L-ASP), and vincristine 
(VCR). Experts have hypothesized how these agents contribute to cognitive late effects, with 
more recent investigation on MTX. Methotrexate interferes with folate metabolism by inhibiting 
the enzyme dihydrofolate reductase (DHFR) from converting dihydrofolates into active folate. 
Folate deficiency results in elevated levels of homocysteine, causing vascular endothelial injury 
and allowing permeability of the blood brain barrier to chemotherapeutic agents. With more 
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 agents in the central nervous system, homocysteine excitotoxicity and neuronal death occurs, 
which may clinically present as focal neurological deficits, stroke-like episodes, and/or seizures 
(Anderson & Kunin-Batson, 2009; Rao et al., 2002). Excess homocysteine may also enhance 
levels of glutamate, which is found in epileptogenic foci, resulting in calcium influx that 
similarly causes excitotoxicity and neuronal death. In general, acute MTX neurotoxicity is 
associated with calcification, hemorrhage, thrombosis, or white matter signal abnormalities (Rao 
et al., 2002). 
Disruptions in the folate and homocysteine systems link to physiological changes in the 
brain as well as neurocognitive late effects. Active MTX therapy has been associated with 
abnormal frontal lobe white matter and working memory deficits at end of treatment, yet the 
long-term effects related to these changes are not clear (Ashford et al., 2010; Khong et al., 2006; 
Reddick et al., 2005a). Smaller white matter tissue volumes have also been significantly 
associated with greater decrements in intelligence, academics, and attention (Reddick et al., 
2006). Reduced frontal lobe white matter volumes in childhood cancer survivors, when 
compared to healthy controls, have been linked with deficits in attention, mathematics, mental 
flexibility, and visual-construction abilities (Carey et al., 2008). Imaging studies employing 
computed tomography (CT) and magnetic resonance imaging (MRI) have revealed calcifications 
at neural pathways that involve intellectual, memory, and attentional abilities (i.e., basal ganglia 
and gray-white matter junctions).  
Glucocorticoids, such as dexamethasone and prednisone, are also a part of leukemia 
treatment. While they demonstrate helpful anti-inflammatory and immunosuppressant functions, 
they also initiate metabolic changes, which may result in seizure experience. Glutamate 
excitotoxicity, particularly occurring in the hippocampus, results in neuronal death (Hoschl & 
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 Hajek, 2001), which also is a potential initiating factor of seizure episodes. Dexamethasone, 
which has a longer half-life than prednisone and other corticosteroids plus more readily 
infiltrates the CNS, is of particular concern when considering the neurocognitive development of 
children undergoing ALL treatment (Bostron et al., 2003; Phipps et al., 2012). Children treated 
with dexamethasone demonstrated a lower mean IQ of 11 points and poorer performance on 
measures of academic achievement and visual-spatial skills as compared to children treated with 
prednisone (Waber et al., 2000).  
Seizure Occurrence among Children Treated for ALL 
Prevalence of Seizures during Leukemia Treatment 
Among the neurological complications seen in leukemia therapy, seizures are one of 
many (e.g., transient ischemic attacks, meningitis, polyneuropathy, transient paresis or paraplegic 
attacks, transient dysarthria, ataxia, aphasic episodes, acute altered mental states such as 
disorientation, loss of consciousness, and irritability, and postintrathecal severe headaches). 
Children with ALL are a specific pediatric cancer population with unique risk factors for and 
pathophysiologic causes of seizure development, such as toxic-metabolic disturbances (Antunes, 
2003). Within the childhood cancer literature, approximately 3 to 13 percent of children treated 
for acute lymphoblastic leukemia (ALL) experience seizures (Fasano & Bergen, 2009; Goldsby 
et al., 2010; Kuskonmaz et al., 2006; Mainero et al., 2000; Maytal et al., 1995; Ochs et al., 1984; 
Skoczen et al., 2004).  
Associated Risk Factors for Seizures 
 Data from a Memorial Sloan-Kettering Cancer Center pediatric oncology database 
revealed that out of 384 children diagnosed with systemic cancer, 47 were positive for seizures 
(Atunes, 2003). Out of the 47 children with underlying cancer and seizures, 22 (46.8 percent) 
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 children were diagnosed with leukemia, and more specifically 16 (34 percent) children with 
ALL. From the sample of 47 children, the age distribution indicated a risk for younger children 
(aged ≤ 10). The sex distribution indicated a slightly higher occurrence of seizures in males (n = 
27), particularly those diagnosed with ALL (Atunes, 2003). This is contrary to the finding by 
Maytal and colleagues (1995) from a sample of 127 children treated for ALL that revealed girls 
at higher risk for seizures than boys. Higher doses of intrathecal and intravenous MTX have been 
previously linked to seizure experience (Ochs et al., 1984). 
Seizure Onset, Type, and Duration 
When treatment-related seizures occur, the onset often takes place during the first six 
weeks of acute induction and consolidation (Fasano & Bergen, 2009). A majority of seizures 
occur between weeks three and four of the induction phase (Gerrard, Eden, & Lilleyman, 1986). 
Consistent with those temporal findings of seizure occurrence in earlier phases of leukemia 
treatment, a study of 1,395 pediatric patients undergoing therapy for ALL who received triple 
intrathecal therapy with or without high-dose MTX revealed that one percent (15 patients) 
experienced seizures: six during induction, four during consolidation, one during interphase, two 
during intensification, and two during maintenance therapy (Dufourg et al., 2010). In a 
retrospective study of adult survivors of childhood ALL, roughly 6 percent (249 out of 3,860 
patients) reported a seizure disorder and over half of those were classified as late-onset: 5 years 
post-diagnosis (Goldsby et al., 2010).  
Regarding seizure type, Ochs and colleagues (1984) observed a majority of seizures 
(93/96) to be primary generalized tonic-clonic (grand mal) or focal motor seizures, with severity 
of seizure classified as status epilepticus for 38 and recurrent for 45. However, these numbers on 
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 seizure type and duration may be reflective of the older, less-refined methods of CNS 
prophylaxis, including high-doses of intrathecal MTX combined with cranial irradiation. 
Pathophysiologic Etiology of Seizures 
Among children treated for ALL, Rao and colleagues (2002, p. 1335) noted that the most 
common etiologies of seizures include “metabolic disturbances, coagulopathy with cerebral 
infarction or venous sinus thrombosis, intracerebral hemorrhage, CNS infection, fever, 
meningeal leukemia and drugs (such as MTX and L-asparaginase).” Kuskonmaz and colleagues 
(2006) noted cerebral thrombosis and ischemic infarction to be the most common etiologies, 
accounting for 40 percent of seizure presentations. The sample included 20 children treated for 
ALL that were reported to have neurological complications, with 10 of them experiencing 
seizures. One possible culprit of intracerebral hemorrhage and thrombosis identified was the 
chemotherapeutic drug, L-asparaginase (L-ASP). The mechanism of action behind L-ASP is 
believed to be declines in proteins that are necessary for proper coagulation and fibrinolysis 
(Kuskonmaz et al., 2006).  
Among a sample of children with leukemia, in addition to metabolic factors, arterial 
hypertension and leukoencephalopathy were observed as common causes of seizures, with 
leukoencephalopathy believed to be the most common etiology (Antunes, 2003). Other 
researchers have observed this same relationship between leukoencephalopathy and treatment-
related seizures. Abnormal structural brain changes were secondary to vascular-related injuries 
of leukemia treatment involving high-dose intravenous and intrathecal chemotherapy, 
specifically white matter damage secondary to methotrexate (Lövblad et al., 1998).  
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 Treatment for Seizures and Prognosis  
It is recommended that children with ALL who experience a first seizure during an early 
treatment phase should undergo brain imaging and coagulation studies (Maytal et al., 1995). If 
tests show no clear etiology, a complete metabolic work-up and cerebral spinal fluid (CSF) 
evaluation is advised to rule out electrolyte imbalance, disease relapse, and infection. Children 
with ALL who have an acute symptomatic seizure without any neuroatypicality or brain lesions 
should be observed closely without AEDs after correction or elimination of etiology of seizure. If 
neuroatypical results are found or seizures reoccur, AEDs are suggested for one to two years or 
until leukemia treatment is complete. However, long-term AEDs are cautioned (Relling et al., 
2000). Treatment modifications may also be appropriate. Reduced dosing or discontinuation of 
chemotherapeutic drugs, such as vincristine, L-asparaginase, or intrathecal MTX, is advised 
(Gerrard et al., 1986). In leukemia treatment protocols with CRT, when feasible, delaying cranial 
irradiation for one to seven months or omitting cranial prophylaxis altogether has been proposed. 
Regarding the prognosis of those who experience treatment-related seizures, Maytal and 
colleagues (1995) reported that 35 percent (6 out of 17 patients) had recurrent seizures, with 28 
percent developing epilepsy (2 out of 17 patients). Dimario and Packer (1990) reported that 13 
percent of their sample (4 of 30 patients) developed epilepsy. In a larger sample of 203 ALL 
patients, Kuskonmaz and colleagues (2006) found that while 5 percent (10 out of 203) 
experienced seizures and 2.5 percent (5 out of 203) developed epilepsy, there was a 50 percent 
risk of developing epilepsy after the first seizure (5 out of 10 patients). Out of the 20 patients 
with neurological complications, 25 percent (5 patients) developed epilepsy.  
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 Cognitive Outcomes Data is Limited 
While the rate of therapy-related seizures among children treated for leukemia is 
established, the cognitive impact of seizures is not well known in this population. Among 
children with CNS relapse, Mulhern and colleagues (1987) found weak negative correlations 
between seizures and overall cognitive and academic functioning. However, a significant 
moderate negative correlation was found between seizures and performance IQ (r = -0.42, p < 
.01). Rao and colleagues (2002) noted that patients experiencing seizures are “at a higher risk for 
… recurrent seizures and delayed intellectual development” (p. 1335). However, little is known 
about the cognitive outcomes and neuropsychological status of ALL survivors that experienced 
treatment-related seizures.  
Behavioral and Psychological Functioning Data is Limited 
 The data for behavioral and psychosocial outcomes of children who experience seizures 
while treated for leukemia is also limited. Fasano & Bergen (2009) followed five adults in their 
mid-late twenties (range = 25-29) who had been diagnosed with ALL before the age seven and 
later developed intractable epilepsy (defined as at least 1 seizure per month), years after ALL 
treatment completion. It is important to note that all five were treated with whole-brain 
irradiation and chemotherapy. Mean years for seizure experience post-treatment was 7.5 years, 
with mean age of seizure experience at age 10.  
Findings indicated that three of the five experienced first seizure during treatment and all 
five were treated with multiple AEDs (Fasano & Bergen, 2009). While three responded to AEDs 
for several years, seizures returned. Only two, who experienced seizure onset during middle 
adolescence, completed high school. All five were cognitively impaired, with one unable to 
maintain employment, one living at home with parents, and two placed in care facilities. The 
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 specific living circumstances of the other two were not reported; however, they were classified 
as borderline intellectual functioning and verbally impaired. 
Neuroimaging Outcomes Data is Limited 
While there is imaging data for children who were treated for leukemia, the data for 
imaging outcomes of children treated for ALL who experience seizures is limited. Rao and 
colleagues (2002) investigated the case of a 27-year-old woman with tonic-clonic seizures who 
was treated with active MTX. MRI revealed enhancement in the meningeal, cortical, and 
subcortical brain regions, as well as focal white matter hyposignal and cerebrospinal fluid (CSF) 
infiltration. CT scan revealed white matter signal abnormalities, thrombosis, ischemic stroke, and 
bilateral parietal hypodensities. CSF exam revealed a slight increase in protein, for which she 
was treated with phenytoin for three months. A follow-up MRI at 10 days later revealed 
resolution in aforementioned enhancements. In this specific case, the pattern of brain damage 
(calcification, hemorrhage, thrombosis, and white matter abnormalities) was classified as acute 
MTX neurotoxicity (Rao et al., 2002).  
Another CT and MRI study examined neuroimaging findings of four children with ALL 
hospitalized for seizures after treated with high-dose intravenous and intrathecal chemotherapy 
(Lövblad et al., 1998). In all four children, CT was positive for diffuse periventricular white 
matter hypodensities and in three of the four children, subcortical hyperdense foci were present. 
In all four cases, MRI revealed diffuse hyper-intense white matter lesions on T2-weighted 
images, which was concordantly observed on susceptibility-sensitive FLASH sequences in the 
CT hyperdense foci as well as T1-weight images of hyperintense foci. Therefore, the authors 
asserted that the white matter lesions with calcification were related to leukoencephalopathy, 
namely a pure form of methotrexate encephalopathy, resulting in seizures (Lövblad et al., 1998).  
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 CURRENT STUDY 
Purpose of this Study 
While the literature reports on the prevalence, onset, prognosis, and treatment of seizures 
during leukemia treatment, and while there is a whole host of data on cognitive outcomes for 
childhood cancer survivors indicating cognitive late effects, little empirical information is 
available regarding specific cognitive outcomes for children treated for ALL who experience 
therapy-related seizures. We desired this information given the importance of identifying 
cognitive risk early in treatment with respect to treatment planning, monitoring, and caregiver 
education. To address this gap in the literature, this study examined the relationship between 
seizures during leukemia therapy and cognitive outcomes in childhood leukemia survivors in the 
hope that it improves these aspects of care. 
Current Study Objectives and Hypotheses 
Our first study objective was to estimate the rate of seizure occurrence in children treated 
for ALL and identify demographic and clinical factors associated with seizure risk, such as age at 
diagnosis, gender, race, treatment intensity, and prior history of seizures. We also examined 
which treatment phases had the highest frequency of seizures. Given the removal of cranial 
irradiation and overall reduction of therapy intensity in the current study protocol, we estimated 
that the rate of seizure occurrence in the current sample was within the low range seen in the 
literature, roughly three to five percent. We predicted that clinical factors of prior history of 
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seizures and therapy intensity would be associated with seizure risk during leukemia therapy, 
with a greater number of seizures occurring during induction and consolidation phases. 
Our second study objective was to assess neurocognitive change in children with therapy-
related seizures by comparing their performance on neuropsychological measures across time 
points of first assessment, end of therapy, and two years post therapy completion. We predicted 
that children who experienced treatment-related seizures would significantly worsen in cognitive 
performance from first assessment to two years post therapy completion. 
Our third study objective was to compare the neuropsychological performance of 
children who experienced therapy-related seizures to the normative sample as well as to the 
performance of a cohort of similarly treated patients without seizures matched on relevant 
variables (i.e., gender, age at treatment, risk arm). We predicted that post-treatment cognitive 
performance among children with treatment-related seizures would be significantly worse 
compared to the normative sample as well as the performance of the matched cohort of similarly 
treated patients without seizures. 
Our fourth study objective was to compare the rate of leukoencephalopathy (i.e., white 
matter damage) between children who experienced therapy-related seizures and the matched 
cohort of similarly treated patients without seizures. We predicted a significantly greater 
occurrence of leukoencephalopathy among children with treatment-related seizures compared to 
similarly treated patients without seizures. 
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METHODOLOGY 
Participants 
 Participants (N = 498) included children enrolled on the St. Jude frontline leukemia 
treatment protocol, Total Therapy 15 (TOTXV), which was the first systematic investigation of 
intensified chemotherapy agents plus optimal intrathecal therapy, without any prophylactic 
cranial irradiation (Pui et al., 2009). Out of the 498 children on protocol, 19 experienced therapy-
related seizures. Out of those 19 children, two children had a prior history of seizures. To 
increase the statistical power of comparisons, each of the 19 children who experienced on-
therapy seizures were matched to two similarly treated children on protocol without seizure 
experience (n= 38). Matching variables included gender, race, age at treatment, and treatment 
intensity. 
Measures 
Measurements included three time points for neuropsychological assessment as well as 
imaging. Neuropsychological testing was conducted at first assessment (week 6 continuation), 
end of therapy (week 120 continuation), and two years post therapy completion. Imaging was 
conducted at the end of 6-week remission induction, week 7 continuation, and end of therapy 
(week 120 continuation).  
 Neuropsychological assessment. Neuropsychological measurements included 
performance-based assessments of overall intellectual functioning, academic achievement, 
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attention and working memory, as well as parental report of behavioral problems. The 
assessment battery has been previously described in detail (Conklin et al., 2012).  
Intellectual functioning. Overall cognitive functioning was measured using age-
appropriate intelligence tests, including the Wechsler Adult Intelligence Scale – Third Edition 
(WAIS-III; Wechsler, 1997; ages > 16), Wechsler Intelligence Scale for Children – Third Edition 
(WISC-III; Wechsler, 1991; ages 6-16), Wechsler Preschool and Primary Scale of Intelligence – 
Revised (WPPSI-R; Wechsler, 1989; ages 3-6), and Bayley Scales of Infant Development – 
Second Edition, Mental Development Index (BSID-II MDI; Bayley, 1993; ages 1-3). All 
Wechsler scores and the BSID-II MDI have an age standardized mean of 100 and standard 
deviation of 15. Estimated Intelligence Quotient (EIQ) scores were obtained at all three 
assessment time-points; whereas Full Scale Intelligence Quotient (FSIQ) scores were obtained at 
the second (end of therapy) and third (two years post therapy completion) assessment time-
points. EIQ was calculated from the Information, Similarities, and Block Design subtests from 
the WAIS-III, WISC-III, or WPPSI-R using a formula provided in Sattler (1992), which 
correlates highly with FSIQs (r = .93).  
 Academic Achievement. Academic achievement was assessed using two subtests from 
the Wechsler Individual Achievement Test (WIAT; Wechsler, 1992): Word Reading and Math 
Reasoning. The WIAT is similar to the other Wechsler (IQ) tests in that it employs age-based 
scores, with a mean of 100 and standard deviation of 15, and was standardized using the same 
sample as the WISC-III. Internal consistency reliabilities for the two subtests are adequate, 
within the high .80s to mid .90s (Wechsler, 1992). Criterion-related validity is adequate as 
moderately high correlations (rs = .70s to .80s) have been observed between the WIAT and 
previously established individually administered achievement tests, such as the Woodcock-
28 
 
 
  
Johnson Psycho-Educational Battery-Revised, Tests of Achievement (rs = .68 to .88), the Wide 
Range Achievement Test-Revised (rs = .69 to .87), the Kaufman Test of Educational 
Achievement (rs = .73 to .87), and the Peabody Picture Vocabulary Test-Revised (rs = .68 to 
.75). Test-retest reliabilities from a sample of 367 students across five grades ranged from the 
mid .80s to low .90s (Wechsler, 1992).  
 Attention, working memory, and processing speed. Participants between the ages of 6 
and 16 were administered the WISC-III, which allowed Wechsler indices of attention, working 
memory, and processing speed to be examined. Indices include Freedom from Distractibility 
(FFD), Digit Span Total (DS), and Processing Speed Index (PSI), respectively. The Conners’ 
Continuous Performance Test (CPT; Conners, 2000a), a computerized measure of selective and 
sustained attention, was also administered to participants aged 6 and older. During the 14-minute 
task, children are instructed to press the space bar as quickly and accurately as possible for letters 
(targets presented at 250ms each), except ‘‘X’’ (non-target, which appears on 10 percent of the 
360 trials). Intervals between stimuli vary by lengths of 1, 2, or 4 seconds depending on the trial 
block. The CPT computes multiple indices and of interest to the current study are indices 
suggesting inattention or failure to respond to a target (Omission Errors) and processing speed 
(Reaction Time). Index scores are age standardized, with a percentile score calculated for 
Omission Errors (mean of 84, standard deviation of 6) and a T-score calculated for Reaction 
Time (mean of 50, standard deviation of 10). Test-retest reliabilities range from .55 to .84 for a 
3-month interval (Conners, 2000a). Construct-related validity is evidenced by differences in 
performance between children with ADHD diagnoses and those without (Seidel & Joschko, 
1990). The CPT has insignificant practice effects for repeat administration, with reliable 
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classification of children with inattention at roughly 87 percent sensitivity and 74 percent 
specificity (Conners, 1995).  
Parent report of behavioral problems and attention abilities. Behavioral problems and 
inattention symptoms were assessed using four subscales of the Conners’ Parent Rating Scale 
(CPRS, Conners 2000b): Learning, Psychosomatic, Impulsive-Hyperactive, and Hyperactive. 
CPRS subscales are age and gender standardized, with a T-score (mean of 50, standard deviation 
of 10). Internal consistency reliabilities range from the mid .80s to mid .90s, with adequate test-
retest reliability. Criterion-related validity is evidenced by significant correlations with the 
Conners’ CPT (r = .44; Conners, 1995).   
Leukoencephalopathy assessment. MRI exams were classified categorically as either 1) 
normal appearing white matter or 2) leukoencephalopathy/white matter damage by 
neuroradiologist, Dr. Fred Laningham, who was blind to neuropsychological assessment. The 
imaging protocol has been previously described in detail (Ashford et al., 2010). Images were 
acquired using a 1.5 Tesla Avanto whole-body MRI scanner with a standard circularly polarized 
volume head coil (Siemens Medical Systems, Iselin, NJ). Leukoencephalopathy, or 
hyperintensities within white matter, is best imaged with a T-2 weighted sequence preferably 
with attenuated cerebrospinal fluid.  
The current protocol quantified images using an automated hybrid neural network 
segmentation and classification method (Reddick, Glass, Cook, Elkin, & Deaton, 1997). Image 
sets included most of the cerebrum, beginning at the apex of the brain, excluding the cerebellum. 
Imaging was obtained using at minimum 19 oblique 4-mm-thick axial images with 1-mm gap. T-
2 weighted images were acquired using a dual spin-echo sequence (TR/TE1/TE2 = 
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3500/17/102ms, 7 echoes). Fluid-attenuated inversion recovery images were acquired with a 
multi-echo inversion recovery sequence (TR/TE/TI = 9000/119/2470 ms; 11 echoes).  
Procedure 
Relevant data was extracted from the TOTXV database as well as through retrospective 
review of medical records for children treated on the TOTXV protocol. 
Data Analytic Strategy 
Prior to analyses, all values were examined to ensure accuracy of data entry. All data 
were screened to detect values outside the range of possibility. Mahalanobis distance detected no 
extreme outliers for exclusion from analyses. An alpha level of .05 was used to assess the 
significance of all statistical comparisons. To characterize the sample, qualitative analyses of 
demographic and clinical variables were performed. Demographic and clinical variables were 
also examined to ensure group equivalence. Cumulative incidence was utilized to estimate the 
rate of seizure occurrence in children treated on TOTXV and identify demographic or clinical 
factors associated with seizure risk. For the following analyses, P values were not adjusted for 
multiple comparisons as it will result in fewer errors of interpretation given that the current data 
being examined are not random numbers but rather actual observations on nature (Rothman, 
1990). One-way repeated measures ANOVA was utilized to assess change in the 
neuropsychological performance of children with therapy-related seizures across three 
assessment time points. One-sample t-tests were utilized to compare the neuropsychological 
performance of children with therapy-related seizures at each time point to published normative 
scores. Mixed Model repeated measures ANOVA was utilized to compare the 
neuropsychological performance of children with therapy-related seizures to the 
neuropsychological performance of a matched non-seizure cohort across time points. Fisher’s 
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exact test was utilized to compare the rates of leukoencephalopathy classification at each 
neuroimaging time point between children with therapy-related seizures and the matched non-
seizure cohort. 
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RESULTS 
Group Equivalence for Age, Race, Gender, and Treatment Intensity 
Descriptive statistics of relevant demographic and clinical variables (i.e., age, race, 
gender, and treatment intensity) were derived to ensure group equivalence on these matched 
variables. Table 1 displays the mean, median, and range of ages for each group at diagnosis. 
Ages ranged from 2 to 18 years old, with a mean age of 8.2 across groups. A one-way between-
groups analysis of variance revealed no statistically significant differences for age across the 
three groups (p = .99). Table 2 displays the remaining relevant variables (i.e., race, gender, and 
treatment intensity). Using Pearson’s Chi-Square Test, no significant differences between the 
seizure and non-seizure cohort groups existed at diagnosis for race, gender, and treatment 
intensity (p = .68; p = .99; p = .99, respectively, Table 2). 
Sample Incidence Rate of Seizures and Associated Factors 
To address the first study objective, the cumulative incidence of children who 
experienced seizures during TOTXV therapy was calculated relative to the entire TOTXV 
sample. Grade 3 seizures were defined as altered consciousness. The estimated 1-year and 2-year 
cumulative incidence rates of Grade 3 and higher seizures were 3.21% ± 0.79% and 3.82% ± 
0.86%, respectively (Figure 1). 
Cumulative incidence curve and estimates were also utilized to identify whether any of 
the selected demographic and clinical variables were statistically associated with risk for on-
therapy seizures. The cumulative incidence of seizure (i.e., first event) was tested between 
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groups by using the method described by Gray (1988) and the estimation was produced by using 
the method described by Kalbfleisch and Prentice (1980). None of the relevant factors of age at 
diagnosis, race, or gender had a statistically significant effect on seizure development (p = .15; p 
= .33; p = .27, respectively, Table 3). Treatment intensity was trending toward statistical 
significance, with Standard/High Risk group having a higher estimated rate than the Low Risk 
group at 2-year cumulative incidence (5.6 ± 1.6 versus 2.5 ± 0.9, respectively, p = .06, Table 3). 
There were no significantly different dosings (mg/m2) of therapeutic agents, which included 
dexamethasone (DEX, p = .96), high dose methotrexate (HDMTX, p = .25), and intrathecal 
therapy (ITHMA: hydrocortisone, methotrexate, and cytarabine/Ara-C, p = .45), between 
children who experienced therapy-related seizures and children who did not (Table 4). 
A frequency count of seizure onset during each treatment phase was calculated and totals 
were transformed into percentages of seizure occurrence by phase (Table 5). The Induction and 
Consolidation phases were the two most prominent phases for Grade 3 seizures to occur, each 
accounting for approximately 26 percent of seizures. Fifty-two percent of seizures occurred 
during these early phases of treatment. 
Cognitive Outcomes Comparisons 
For the second objective, we conducted a one-way repeated measures ANOVA to assess 
the neuropsychological performance of children with therapy-related seizures across three time 
points: first assessment, end of therapy, and two years post therapy completion. The means and 
standard deviations are presented in Table 6. There was no significant change in estimated 
intellectual functioning (EIQ) scores across the three time points for children who experienced 
seizures (p = .45). A statistically significant difference was found for basic reading scores from 
baseline to 2 years post therapy, with a worsening trend (-7.43 points, p = .01). There were no 
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significant differences across measurements of math reasoning, attention, working memory, or 
processing speed (p = .39; p = .76; p = .38; p = .82, respectively). Freedom from Distractibility 
approached significance for a worsening trend from end of treatment to 2 years post (p = .06). 
Parental report on the Conners’ indicated significant improvement in Learning from baseline to 2 
years post (-19.56 points, p = .01). None of the other Conners’ rating scales revealed significant 
differences, although improvements in Hyperactivity approached significance (p = .06). 
To address the third study objective, we conducted one-sample t-tests to compare 
cognitive performance of children who experienced therapy-related seizures to published 
normative scores at each of the three assessment time points. The means and standard deviations 
for respective time points are presented in Tables 7, 8, and 9. At first assessment, there was a 
statistically significant difference for estimated IQ, with the seizure group having a lower mean 
IQ of 89 compared to normative mean IQ of 100, p = .01. There were no significant differences 
between the seizure group and normative scores for measures of academics, inattention, or 
processing speed. Lastly, at first assessment, the Conners’ Parent Rating Scale revealed 
significantly more psychosomatic problems in the seizure group (M = 68.64) than the norm 
group (M = 50), p < .01. In comparison to normative scores at end of therapy (week 120), 
significant differences for IQ were no longer present; however, the seizure group performed 
significantly worse on working memory tasks (FFD = 80.14 vs. 100 norm, p = .02; DS Total = 
6.43 vs. 10 norm, p = .03) and their parents reported greater psychosomatic problems (65.00 vs. 
50 norm, p = .02). At two years post therapy completion, the same pattern was observed for 
working memory as the seizure group performed significantly worse than the norm (FFD = 79.43 
vs. 100 norm, p = .01; DS Total = 6.00 vs. 10 norm, p = .02) as well as parental report of 
psychosomatic problems (65.70 vs. 50 norm, p = .03).  
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We conducted a Mixed Model repeated measures ANOVA (between and within subjects 
factors) to compare cognitive performance of children who experienced treatment-related 
seizures to the matched cohort of children on protocol without seizures across the three time 
points (first assessment, end of therapy, and two years post therapy completion). The means and 
standard deviations for respective time points are presented in Tables 10, 11, and 12. At first 
assessment, the seizure group demonstrated a significant difference for lower estimated IQ when 
compared to the non-seizure cohort group (89.33 vs. 100.74, p = .05). There were no other 
significant differences in cognitive functioning or parental report of behavioral problems at first 
assessment. In comparison to the non-seizure cohort group at end of therapy (week 120), the 
seizure group performed significantly worse on attention and working memory tasks (FFD = 
80.14 vs. 100.74, p < .01; DS Total = 6.43 vs. 9.52, p = .05). Parents of children who 
experienced therapy-related seizures reported greater learning problems, impulsivity, and 
hyperactivity (62.27 vs. 49.69, p = .04; 59.36 vs. 48.65, p = .04; 57.45 vs. 49.59, p = .04, 
respectively). At two years post in comparison to the non-seizure cohort group, the seizure group 
performed significantly worse on a measure of overall intelligence (FSIQ = 88.92 vs. 101.00, p = 
.04). The same pattern of the seizure group performing significantly worse than the non-seizure 
cohort group on measures of attention and working memory was observed (FFD = 79.43 vs. 
101.17, p < .01; DS Total = 6.00 vs. 10.04, p = .01), with additional processing speed deficits in 
the seizure group (PSI = 88.57 vs. 103.92, p = .02). There were no significant elevations on 
parental report of behavioral problems for the seizure group in comparison to the non-seizure 
cohort group. 
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Imaging Comparisons 
For the final objective, we used Fisher’s exact test to compare the rates of 
leukoencephalopathy classification between children with treatment-related seizures and 
similarly treated children without seizures. Results are reported in Table 13. Significant 
differences on MRI were observed between the seizure and cohort groups at second time point of 
week 7 continuation (56% vs. 12.9%, p < .01) and third time point of end of therapy (week 120: 
38% vs. 6%, p = .01) but not at the first imaging time point of week 5 remission (15.38% vs. 
2.94%, p = .18).  
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DISCUSSION 
Results from this study revealed that two-year incidence of therapy-related seizures for 
children treated on the TOTXV protocol was 3.82%, which is a relatively positive outcome given 
that it falls within the lower range of 3 to 13 percent seizure incidence found in the literature. 
This lowered incident rate, in comparison to the larger literature, is likely reflective of the 
lessened neurotoxic effect of chemotherapy-only protocols on neurodevelopment and cognitive 
late effects. Contrary to a priori hypotheses, demographic or clinical factors such as prior seizure 
history or intensity of chemotherapy were not statistically significant predictors of seizure 
development. Although, a trend for standard/high treatment intensity was observed for seizure 
risk (p = .06). Over 50 percent of seizures observed in this study occurred during the induction 
and consolidation phases, consistent with historical findings of seizures during early phases of 
treatment in which chemotherapy doses are typically at its highest. 
Of particular interest is the notable lack of significant change in neuropsychological 
performance for children with therapy-related seizures when compared to themselves across 
treatment time points. Measures of overall intellectual functioning, math reasoning, attention, 
working memory, and processing speed did not significantly differ from first assessment to two 
years post therapy completion. The only exception was performance on a measure of basic 
reading, which significantly worsened from first assessment to two years post therapy. One 
potential explanation for this contrary finding is that first assessment was not a true baseline, as 
four doses of high dose methotrexate (HDMTX) were administered prior to first  
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neuropsychological assessment. It is possible that intensified chemotherapy agents were already 
influencing cognitive performance at first assessment. This ‘artifact baseline’ hypothesis may 
also explain parents’ reports on the CPRS of significantly reduced learning problems from first 
assessment to two years post therapy completion. Parents of children with treatment-related 
seizures may have already been observing learning problems at first assessment, which they 
acclimated to two years post therapy. Another plausible explanation, given that end of therapy 
corresponded with school re-entry for many children, is that learning problems may have been 
particularly notable for parents at therapy completion (second assessment). School 
accommodations and reintegration into the social learning environment may have lessened these 
issues over time.  
Although there was a broad lack of neuropsychological change within the seizure group 
across time, when the neuropsychological performance of the seizure group was compared to 
normative sample scores, patterns of differences emerged and maintained across assessment time 
points. Significant differences were observed in domains of attention, working memory, 
processing speed, and parental report of psychosomatic problems for children with therapy-
related seizures. This finding is consistent with previous literature that supports cognitive late 
effects, namely impaired attention and working memory abilities, in children treated for ALL 
(Ashford et al., 2010; Conklin et al., 2012; Phipps et al., 2012).   
Similar patterns for attention, working memory, and processing speed also emerged 
during comparisons of neuropsychological performance across assessments between the seizure 
group and the non-seizure cohort. At leukemia therapy completion, children with therapy-related 
seizures performed significantly worse for attention and working memory tasks than the matched 
cohort, and these deficits persisted two years later with the addition of processing speed deficits. 
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Results also revealed that children with treatment-related seizures performed significantly worse 
on a measure of estimated intelligence at first assessment and also on a full-scale measure of 
intelligence (FSIQ) at two years post therapy completion when compared to the matched cohort. 
The ‘artifact baseline’ hypothesis likely also explains significant differences for estimated 
intellectual functioning at first assessment. However, the finding for decreased overall 
intelligence at two years post therapy alongside problems in attention, working memory, and 
processing speed deficits is of particular interest. Given these concurrent findings, it is possible 
that early cognitive late effects of attention and working memory problems among children who 
experienced on-therapy seizures may precede later declines observed in overall IQ. It is 
important to also mention that at therapy completion, the seizure group parents reported 
significantly more problems with learning, impulsivity, and hyperactivity than parents of non-
seizure cohorts, but these differences become insignificant by two years post therapy completion 
as group scores are nearly the same. As aforementioned, end of therapy corresponds with school-
reentry for many children, such that learning and behavioral problems may be even more salient 
for parents of children with treatment-related seizures, which lessen over time with school 
accommodations. 
This study’s imaging findings indicated that children with therapy-related seizures 
experienced more significant early neurotoxicity (i.e., leukoencephalopathy as indicated by white 
matter hyperintensities on MRI) than non-seizure cohorts, which likely contributes to higher 
levels of cognitive late effects observed among children with on-therapy seizures. Further 
supporting the early cognitive late effect hypothesis, significant differences in treatment-induced 
leukoencephalopathy between the seizure group and cohort group were observed concurrently 
with significantly worse neuropsychological performance for the seizure group in comparison to 
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the cohort group on measures of estimated intellectual functioning, attention, and work memory. 
This observation is consistent with previous empirical findings of decreased abilities on attention 
and working memory tasks to be associated with treatment-related neuroanatomical changes 
such as smaller and abnormal cerebral white matter volumes (Ashford et al., 2010; Khong et al., 
2006; Reddick et al., 2005a; Reddick et al., 2006). Smaller white matter tissue volumes have also 
been related to larger declines in intelligence and academics (Reddick et al., 2006).  
Rates of leukoencephalopathy prevalence for this study were also consistent with 
previous literature indicating a rise in white matter lesions after several intravenous HDMTX 
rounds, followed by reductions in white matter damage at therapy completion (Reddick et al., 
2005). Therefore, the observed abnormal structural brain changes in cerebral white matter are 
likely subsequent to on-therapy vascular-related injuries, namely a form of HDMTX 
encephalopathy (Lövblad et al., 1998).  While metabolic factors and arterial hypertension 
undoubtedly play a role in seizure risk, leukoencephalopathy is a probable common etiology of 
treatment-related seizures in this study.  
A major implication of these neurocognitive findings for children who experienced 
therapy-related seizures while treated for ALL is the provision of preliminary yet promising 
information that may assist with treatment planning, monitoring of cognitive outcomes, and 
caregiver education, all with the ultimate end goal of improving quality of life for this growing 
group of survivors. Based on this study’s observations, it appears that children who experienced 
treatment-related seizures are at greater neurocognitive risk when compared to matched cohorts 
without seizures. The task then presented is to detect how and when we can best identify 
significant changes in neurocognitive status that indicate risk for long-term CNS effects. 
Performance-based and imaging-based measures have demonstrated to be sensitive and specific 
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indicators of neurotoxicity. Utilizing these methods as appropriate in the early phases of 
chemotherapy, coupled with sophisticated clinical observation (e.g., seizure occurrence as 
treatment intensifies), is likely to lead to earlier detection of children at risk for CNS effects. 
Earlier detection would allow for earlier interventions and treatment modifications that may 
mitigate the neurotoxic effects of high-dose chemotherapy on the neurodevelopment of 
childhood cancer survivors. 
Domain-specific neuropsychological testing combined with more advanced 
neuroimaging such as magnetic resonance diffusion tensor imaging (DTI) may help in the early 
identification of subtle cerebral white matter damage. The earliest identification of even subtle 
changes in neurocognitive status could make the utmost difference for medical researchers and 
physicians developing more effective therapies that result in fewer cognitive late effects and 
mitigate other side effects such as leukoencephalopathy and seizures. Identification would better 
inform each patients’ treatment plan with enhanced physician insight on when regimen-related 
accommodations are needed, such as modifying the timing or dosing of chemotherapy 
administrations to minimize white matter damage or seizure risk without sacrificing a favorable 
prognosis. Identification would also allow healthcare professionals to develop patient-centric 
medical regimens that not only implement therapeutic interventions targeted at domain-specific 
cognitive rehabilitation, but enact preventative therapy that may serve as a cognitive protective 
factor against lasting therapy-related CNS impairments. For patients and their caregivers, early 
identification of treatment-related neurocognitive deficits would allow them to develop 
compensatory and remedial strategies to minimize therapy-related impairments, which is likely 
to result in improved prognosis and reintegration into classroom and social settings.  
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Recent empirical findings for neurocognitive interventions that lessen cognitive late 
effects appear promising for the expanding cancer survivorship population. These interventions 
comprise pharmacologic and non-pharmacologic methods that rely heavily on the cognitive 
rehabilitation literature for traumatic brain injury, childhood ADHD, and dementia (Davis et al., 
2013; Phipps et al., 2012). Psychostimulant medication used to mitigate attention deficits in 
children diagnosed with ADHD, specifically methylphenidate (MPH), has demonstrated similar 
positive attentional benefits in childhood cancer survivors (Conklin et al., 2007; Davis et al., 
2013; Mulhern et al., 2004; Thompson et al., 2001). Medications used to treat mild to moderate 
dementia, such as donepezil, have also been under examination and preliminary results suggest 
improvement in cognitive function as well as mood and health-related quality of life (Castellino 
et al., 2012; Shaw et al., 2006). There is also a movement towards using pharmacological 
interventions as neuroprotective agents during treatment, such as the anti-Alzheimer drug 
memantine to prevent cognitive decline related to oxidative stress in the CNS (Brown et al., 
2012). However, medication side effects, parental disapproval, and medical contraindications 
may interfere with the feasibility pharmacological interventions. Non-pharmacological 
interventions such as the Cognitive Remediation Program (CRP, Butler & Copeland, 2002) and 
CogMed© Working Memory Training (Klingberg et al., 2002; Klingberg et al., 2005) have 
developed as an alternative to medication. Butler and colleagues (2008) multicenter, randomized 
clinical trial of CRP produced promising results for 167 childhood cancer survivors, including 
modest effect size within the .5 range, parental report of significant improvements in attention, 
and gains on measures of academic abilities in language and mathematics. CogMed’s well-
demonstrated efficacy for remediation of attention deficits in children diagnosed with ADHD has 
encouraged researchers to begin exploring this targeted working memory program in childhood 
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cancer survivors (Conklin et al., 2013; Hardy, Carlson-Green, & Conklin, 2012; Hardy, Willard, 
Allen, & Bonner, 2012). While a computer-based treatment is favored due to its portable nature 
and limited staffing needs, research continues to investigate the feasibility, generalizability, and 
continuation of benefits following computerized intervention. The Pediatric Cancer Genome 
Project, led by St. Jude Children’s Research Hospital and Washington University School of 
Medicine, also offers hope of identifying genetic markers of greater risk for cognitive late effects 
in those diagnosed with ALL.  
Limitations and Future Directions 
The current findings should be interpreted within the context of study limitations. One 
limitation of this study is its retrospective nature. A prospective, longitudinal study would allow 
for a more systematic investigation of the emergence of cognitive late effects, including potential 
mechanisms of change. Efforts are directed toward conducting earlier baseline assessments, yet 
this is difficult due to children being sick, needing immediate medical treatment, and receiving 
high-dose steroids. None of which are positive factors for valid and reliable estimates of 
cognitive function. Future studies would also benefit from timing neuropsychological 
assessments to correspond with neuroimaging assessments for more exact comparisons. 
Likewise, for this study, an additional imaging time point at two years post therapy would have 
been helpful in examining whether hypothesized declines in leukoencephalopathy, which were 
observed at end of treatment in our sample, continue beyond therapy completion. 
In regard to study measures, although EIQ is highly correlated with FSIQ, the use of an 
estimated intelligence measure at first assessment likely limited sensitivity to detect 
neurocognitive changes in overall intellectual functioning. It also made comparisons to later 
assessments of full-scale intellectual functioning less appropriate. Careful replication of the 
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finding for declines in overall intelligence with sensitive measures throughout is warranted. It 
was also difficult to interpret CPRS findings as they were often inconsistent with neurocognitive 
performance scores. The lack of correlation between parent report and performance-based 
measures may be one of the unfortunate yet expected drawbacks of subjective rater measures, 
which have previously been shown to exhibit low rates of sensitivity and specificity for 
performance-based changes in childhood cancer populations (Howarth et al., 2013). While it 
could be that problematic child behaviors such as learning difficulties and hyperactive-
impulsivity significantly alleviated post-treatment, it may also be that parents are relatively 
limited to gross assessments of behavioral changes, relying on salient factors such as grades in 
school or misconduct within the school and home environments. 
In recent years, neuroimaging methods have advanced from basic structural MRI to more 
sophisticated techniques, such as magnetic resonance spectroscopy, volumetrics, and diffusion 
tensor imaging (DTI). Future studies will benefit from DTI specifically as it enables the 
examination of location, orientation, and anisotropy of white matter pathways associated with 
neuroanatomical models of attention and memory, such as the prefrontal cortex, in relation to 
chemotherapy-induced cognitive late effects. Preliminary findings of DTI studies indicate greater 
frontal white matter changes after chemotherapy than before treatment in children treated for 
hematological malignancies, such as ALL (Morioka et al., 2013). Decreased white matter 
diffusion anisotropy observed after cancer treatment has also been associated with significant 
negative effects on IQ (Khong et al., 2006). A recent review of DTI within the context of 
chemotherapy-induced neurocognitive impairment, drawing from longitudinal and cross-
sectional data, indicates that current studies confirm the relationship between abnormal cerebral 
45 
 
 
  
white matter and impaired cognitive performance (Deprez, Billiet, Sunaert, & Leemans, 2013). 
Therefore, assessment of white matter pathways via DTI is likely to be a valuable clinical tool 
for measurement of treatment-induced neurotoxicity in childhood cancer survivors. 
Conclusions 
There has been growing empirical evidence of cognitive late effects for survivors of acute 
lymphoblastic leukemia. While demographic and clinical factors have been associated with 
greater likelihood of cognitive late effects in leukemia therapy (i.e., younger age at diagnosis, 
female gender, higher treatment intensity, and greater time since treatment), this study’s aim was 
to understand the impact of treatment-related seizures as an indicator of neurotoxicity with 
associated cognitive decline and subsequent cognitive late effects.  
Despite this study’s limitations, the current findings point to a relationship between on-
therapy seizures, leukoencephalopathy, and deficits in neuropsychological functioning, 
specifically attention, working memory, and processing speed skills, which may lead to overall 
declines in intellectual functioning. However, these findings also raise questions about the 
neurobehavioral mechanisms, including neuroanatomical pathways, involved in cognitive late 
effects associated with seizures. Future research on theoretically driven neurobehavioral 
processes is necessary to unravel these mechanisms within the context of leukemia therapy so 
that we may improve caregiver education, treatment planning, and treatment monitoring for as 
many children as possible. 
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Table 1 
Means, Standard Deviations, Medians, and Ranges of Ages Across Groups at Diagnosis 
  Total  Seizure Group  Cohort 1    Cohort 2      p-value  
N     57            19       19          19                   0.99A  
Mean (SD)    8.26 (4.72)    8.27 (4.80)           8.26 (4.81)          8.23 (4.82)  
Median  7.66          7.21        8.00        7.66 
Range           2.07-18.73    2.07-18.73           2.09-17.12          2.14-18.73 
A Analysis of Variance 
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Table 2 
Race, Gender, and Treatment Intensity Across Groups at Diagnosis 
     Total  Seizure Group  Cohort 1    Cohort 2      p-value  
N       57           19       19          19            
Race [n (%)]                 0.68P 
     White  42 (73.7)      14 (73.7)            13 (68.4)    15 (78.9) 
     Black  14 (24.6)        5 (26.3)              5 (26.3)      4 (21.1) 
     Other     1 (1.8)             0 (0)     1 (5.3)           0 (0)    
Gender [n (%)]                0.99P 
     Male  39 (68.4)       13 (68.4)            13 (68.4)              13 (68.4) 
     Female  18 (31.6)                6 (31.6)   6 (31.6)                6 (31.6) 
Treatment Intensity [n (%)]               0.99P 
     Low  21 (36.8)                7 (36.8)   7 (36.8)                7 (36.8) 
     Stand/High  36 (63.2)       12 (63.2)            12 (63.2)     12 (63.2) 
P Pearson’s Chi-Square Test 
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Figure 1 
Cumulative Incidence of ≥Grade 3 Seizures on TOTXV 
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Table 3 
Cumulative Incidence of Seizures by Relevant Factors 
Factors    N   Year 1   Year 2      p-value  
Age at Diagnosis                0.15G 
     <5 Yrs   235  1.3 ± 0.7  2.6 ± 1.0 
     Others   263  4.9 ± 1.3  4.9 ± 1.3 
Race                        0.33G 
     White   402  2.7 ± 0.8  3.5 ± 0.9  
     Black     79  6.3 ± 2.8  6.3 ± 2.8 
     Other      17        0           0  
Gender                  0.27G 
     Male   279  3.9 ± 1.2  4.7 ± 1.3 
     Female   219  2.3 ± 1.0  2.7 ± 1.1 
Treatment Intensity                 0.06G 
     Low   284  1.4 ± 0.7  2.5 ± 0.9 
     Stand/High   214  5.6 ± 1.6  5.6 ± 1.6 
G Gray’s Test 
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Table 4 
Total Dose of Drug (mg/m 2) Received Before First Seizure Event Across Groups 
             Total (n=57)      Seizure Group (n=19)        Cohorts (n = 38)         p-value 
DEX                        0.96 
     Mean (SD)         151.37 (232.34)          149.36 (234.15)             152.38 (234.58) 
     Max     866.62                 858.17         866.62       
HDMTX                       0.25 
     Mean (SD)    11070.73 (8780.95)         9193.60 (7840.70)       120009.29 (9169.41)                                  
     Max             32263.77                       26401.27                  32263.77        
ITHMA                       0.45 
     Mean (SD)          69.64 (47.33)           62.94 (46.09)               73.00 (48.19) 
     Max               144.00                          132.00                             144.00 
 
 
 
 
 
 
 
 
 
 
73 
 
 
  
Table 5 
Frequency Count and Percent of Seizure Onset Across Treatment Phases 
       Frequency   Percent 
Pre-Treatment             1     5.26% 
Induction             5                  26.32% 
Consolidation             5              26.32% 
Continuation Weeks 1-6           1                5.26% 
Continuation Weeks 10-16                      3              15.79% 
Continuation Weeks 48-95                      1                5.26% 
LR Continuation Weeks 20-47          2              10.53% 
LR Continuation Weeks 21-47               1                5.26% 
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Table 6 
Means and Standard Deviations on Cognitive Measures for Seizure Group Across Time Points  
                  First Assess (Wk 6)        End Therapy (Wk 120)       2 Yrs Post      p-value 
Wechsler EIQ        89.33 (10.10)                    90.73 (19.82)             94.33 (18.84)   0.45 
Wechsler FSIQ  --           88.20 (21.29)             88.92 (18.35)     --
FFD    --           80.14 (17.86)         79.43 (15.11)        0.06     
PSI     --           86.29 (24.31)         88.57 (18.04)   0.82 
DS Total    --               6.43 (3.60)             6.00 (4.00)   0.38 
WIAT  
    Basic Reading         93.33 (7.39)          90.80 (22.38)        86.56 (22.26)   0.01* 
    Math Reasoning      91.83 (16.79)          87.00 (19.30)        89.67 (22.47)   0.39 
Conners’ CPT  
    Omissions     86.15 (21.79)          89.43 (12.69)        83.04 (21.33)   0.76 
    Hit RT                  51.04 (9.69)                    50.84 (13.81)        53.27 (15.59)   0.92 
CPRS  
    Learning    63.27 (23.43)          62.27 (18.66)          44.00 (9.21)   0.01* 
    Psychosomatic          68.64 (17.29)          65.00 (19.54)             65.70 (20.39)   0.74 
    Impulse-Hyper          56.36 (15.36)          57.45 (11.47)           50.50 (9.81)   0.28 
    Hyperactive    59.73 (20.56)          59.36 (17.03)           46.60 (9.34)   0.06 
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Table 7 
Comparisons on Cognitive Measures Between Seizure Group and Normative Sample at First 
Assessment (Week 6) 
                    Seizure Group   Normative Sample       p-value 
Wechsler EIQ                  89.33 (3.37)                             100 (15)     0.01* 
WIAT  
    Basic Reading          93.33 (3.02)           100 (15)       0.07 
    Math Reasoning               91.83 (6.61)                      100 (15)     0.27 
Conners’ CPT  
    Omissions               86.15 (9.75)             84 (6)     0.83 
    Hit RT                         51.04 (4.33)             50 (10)      0.82 
CPRS  
    Learning             63.27 (7.06)             50 (10)     0.08 
    Psychosomatic                   68.64 (5.21)             50 (10)             < 0.01* 
    Impulse-Hyper                   56.36 (4.63)             50 (10)     0.19 
    Hyperactive             59.73 (6.20)             50 (10)     0.14 
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Table 8 
Comparisons on Cognitive Measures Between Seizure Group and Normative Sample at End of 
Therapy (Week 120) 
                    Seizure Group   Normative Sample       p-value 
Wechsler EIQ                  90.73 (5.98)                             100 (15)     0.15 
Wechsler FSIQ   88.20 (6.73)                             100 (15)     0.11 
FFD     80.14 (6.75)                             100 (15)     0.02* 
PSI      86.29 (9.19)                             100 (15)     0.18 
DS Total      6.43 (1.36)                               10 (3)     0.03* 
WIAT  
    Basic Reading                 90.80 (7.08)                             100 (15)     0.22 
    Math Reasoning                87.00 (6.10)                             100 (15)     0.06 
Conners’ CPT  
    Omissions                89.43 (4.23)              84 (6)                0.23 
    Hit RT                          50.84 (4.60)             50 (10)     0.85 
CPRS  
    Learning              62.27 (5.62)             50 (10)     0.05* 
    Psychosomatic                    65.00 (5.89)             50 (10)     0.02* 
    Impulse-Hyper                    57.45 (3.46)             50 (10)     0.05* 
    Hyperactive              59.36 (5.14)             50 (10)     0.09 
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Table 9 
Comparisons on Cognitive Measures Between Seizure Group and Normative Sample at Two 
Years Post-Therapy 
                    Seizure Group   Normative Sample       p-value 
Wechsler EIQ                  94.33 (5.44)                             100 (15)     0.31 
Wechsler FSIQ   88.92 (5.30)                             100 (15)     0.06 
FFD     79.43 (5.71)                             100 (15)     0.01* 
PSI      88.57 (6.82)                             100 (15)     0.14 
DS Total      6.00 (1.41)                               10 (3)     0.02* 
WIAT  
    Basic Reading                 86.56 (7.42)                             100 (15)     0.10 
    Math Reasoning                89.76 (7.49)                             100 (15)     0.20 
Conners’ CPT  
    Omissions               83.04 (6.43)              84 (6)                0.88 
    Hit RT                          53.27 (4.70)             50 (10)     0.50 
CPRS  
    Learning              44.00 (2.91)             50 (10)     0.06 
    Psychosomatic                    65.70 (6.45)             50 (10)     0.03* 
    Impulse-Hyper                    50.30 (3.10)             50 (10)     0.92 
    Hyperactive              46.60 (2.95)             50 (10)     0.27 
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Table 10 
Comparisons on Cognitive Measures Between Seizure Group and Matched Cohort at First 
Assessment (Week 6) 
                    Seizure Group       Cohort Group       p-value 
Wechsler EIQ                  89.33 (3.37)                         100.74 (3.18)    0.05* 
WIAT  
    Basic Reading          93.33 (3.02)       102.45 (3.09)      0.10 
    Math Reasoning               91.83 (6.61)                  104.65 (3.28)    0.08 
Conners’ CPT  
    Omissions              86.15 (9.75)        72.49 (6.86)    0.22 
    Hit RT                         51.04 (4.33)         44.42 (3.31)     0.37 
CPRS  
    Learning             63.27 (7.06)        50.03 (1.71)    0.19 
    Psychosomatic                   68.64 (5.21)        67.17 (3.30)    0.74 
    Impulse-Hyper                   56.36 (4.63)        50.23 (1.73)    0.22 
    Hyperactive             59.73 (6.20)        49.13 (1.57)    0.17 
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Table 11 
Comparisons on Cognitive Measures Between Seizure Group and Matched Cohort at End of 
Therapy (Week 120) 
                    Seizure Group       Cohort Group       p-value 
Wechsler EIQ                  90.73 (5.98)                         100.41 (2.81)    0.14 
Wechsler FSIQ   88.20 (6.73)                           97.61 (2.29)    0.21 
FFD     80.14 (6.75)                         100.74 (2.67)            < 0.01* 
PSI      86.29 (9.19)                         100.74 (3.37)    0.14 
DS Total      6.43 (1.36)                            9.52 (0.50)    0.05* 
WIAT  
    Basic Reading                 90.80 (7.08)                        102.04 (2.62)    0.22 
    Math Reasoning                87.00 (6.10)                        100.46 (2.45)    0.07 
Conners’ CPT  
    Omissions               89.43 (4.23)       84.42 (3.26)     0.51 
    Hit RT                          50.84 (4.60)       47.42 (1.90)     0.50 
CPRS  
    Learning              62.27 (5.62)       49.69 (2.35)     0.04* 
    Psychosomatic                    65.00 (5.89)       56.41 (3.19)     0.16 
    Impulse-Hyper                    57.45 (3.46)       49.59 (2.08)     0.04* 
    Hyperactive              59.36 (5.14)       48.66 (2.03)     0.04* 
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Table 12 
Comparisons on Cognitive Measures Between Seizure Group and Matched Cohort at Two Years 
Post-Therapy 
                    Seizure Group      Cohort Group       p-value 
Wechsler EIQ                  94.33 (5.44)                        101.64 (2.87)    0.29 
Wechsler FSIQ   88.92 (5.30)                        101.00 (2.77)    0.04* 
FFD     79.43 (5.71)                        101.17 (3.58)            < 0.01* 
PSI      88.57 (6.82)                        103.92 (2.59)    0.02* 
DS Total      6.00 (1.41)                         10.04 (0.68)    0.01* 
WIAT  
    Basic Reading                 86.56 (7.42)                       101.53 (2.79)    0.07 
    Math Reasoning                89.76 (7.49)                       100.20 (2.65)    0.22 
Conners’ CPT  
    Omissions               83.04 (6.43)       78.32 (3.18)     0.19 
    Hit RT                          53.27 (4.70)       52.52 (1.97)     0.61 
CPRS  
    Learning              44.00 (2.91)       46.71 (2.76)     0.37 
    Psychosomatic                    65.70 (6.45)       68.71 (3.94)     0.48 
    Impulse-Hyper                    50.30 (3.10)       47.00 (2.66)     0.35 
    Hyperactive              46.60 (2.95)       47.47 (3.35)     0.70 
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Table 13 
Comparisons of Leukoencephalopathy on MRI Between Seizure Group and Matched Cohort 
Across Time Points 
                     Seizure Group     Cohort Group       p-value 
Baseline [n (%)]            0.18 
    Leuko                    2 (15.38)                            1 (2.94)     
    Normal                         11 (84.62)        33 (97.06)   
Week Post-First Assessment [n (%)]                  < 0.01* 
    Leuko                  9 (56.25)           4 (12.90)    
    Normal                                       7 (43. 75)         27 (87.10)      
End of Therapy [n (%)]           0.01* 
    Leuko                 5 (38.46)            2 (6.06)      
    Normal                8 (61.54)        31 (93.94)      
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Part-time position 
 assisted with scheduling clients and clinical filing, observed and 
participated in therapy sessions, and created an anger management game 
for children 
Supervisors: Dodie Ward, M.S., L.P.T.; Kim Zweifler, Ph.D. 
 
     2003-2000 Physical Therapist Aide 
  Providence Hospital, Mobile, AL 
Part-time position 
 scheduled and transported patients; aided in wound care dressing removal 
and application, aided in gait training and therapeutic exercises 
 utilized hospital software MediServe and Invision; retrieved medical 
records, lab results, supplies, and medications 
Supervisors: Loverette Vaughn, Office Coordinator; Kathy Mignone, P.T.A. 
 
 
Professional Training 
     2010 ACT Summer Institute at the University of Nevada, Reno 
2009           Vincent Carbone’s Verbal Behavior Therapy at Hernando Elementary School, 
Hernando, MS 
     2008 ACT Summer Institute at the Illinois Institute of Technology, Chicago, IL 
2007-2006 Center for Pediatric Neuropsychology Rounds at Le Bonheur Children’s Medical 
Center, Memphis, TN 
2006 ACT Advanced Practice Workshop at The University of Mississippi, University, 
MS 
2005 ACT Experiential Workshop at Camp Hopewell, Oxford, MS 
2004 ACT Summer Institute and Introductory Experiential Workshop at the University 
of Nevada, Reno 
 
 
Grants 
Gustafson, S., & Nassar, S. L. (2010). Clinical Training: Creation of a Service Consortium. 
United States Department of Health and Human Services, Health Resources and 
Service Administration ($377,123.00, unfunded) 
 
 
Publications 
Nassar, S. L., Berkout, O. V., & Wilson, K. G. (in preparation). Preliminary Psychometric 
Properties of the Valued Living Questionnaire–II: An Expanded Measure of Values 
and Committed Action. 
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Nassar, S. L., Conklin, H. M., Ashford, J. M., Reddick, W. E., Glass, J. O., Jeha, S., Zhou, Y., 
Cheng, C., & Pui, C-H. (in preparation). Cognitive outcomes in children experiencing 
seizures during treatment for Acute Lymphoblastic Leukemia. 
 
Gustafson, S. A., Nassar, S. L., & Waddell, D. E. (in preparation). Neurotherapy of neurally 
mediated syncope: A single case design. Journal of Neurotherapy. 
 
Bethay, J. S., Wilson, K. G., Schnetzer, L. W., Nassar, S. L., & Bordieri, M. J. (2012). A 
controlled pilot evaluation of Acceptance and Commitment Training for intellectual 
disability staff. Mindfulness, Online First. doi: 10.1007/s12671-012-0103-8 
 
Wilson, K. G., Flynn, M. K., Bordieri, M., Nassar S. L., Lucas, N. N., & Whiteman. K. C. 
(2011). Acceptance and Cognitive Behavior Therapy. In W. O’Donohue & J. E. Fisher 
(Eds.) Cognitive Behavior Therapy: Core Principles for Practice. Hoboken, NJ: Wiley. 
 
Waddell, D. E., Nassar, S. L., & Gustafson, S. A. (2011). Single-case design in 
psychophysiological research. Part II: Statistical analytic approaches. Journal of 
Neurotherapy, 15(2), 160-169. 
 
Gustafson, S. A., Nassar, S. L., & Waddell, D. E. (2011). Single-case design in 
psychophysiological research. Part I: Context, structure, and techniques. Journal of 
Neurotherapy, 15(1), 18-34. 
 
Nassar, S. L. (2010). A measure of interest to logotherapy researchers: The Death Depression 
Scale. The International Forum for Logotherapy, 33(1), 56-57. 
 
Nassar, S. L. (2009). A measure of interest to logotherapy researchers: The Valued Living 
Questionnaire. The International Forum for Logotherapy, 32(2), 121-122. 
 
Nassar, S. L. (2009). A measure of interest to logotherapy researchers: The Meaningful Life 
Measure. The International Forum for Logotherapy, 32(1), 56-57. 
 
Nassar, S. L. (2008). A measure of interest to logotherapy researchers: The Satisfaction With 
Life Scale. The International Forum for Logotherapy, 31(2), 114-115. 
 
Nassar, S. L. (2008). A measure of interest to logotherapy researchers: The Hope Scale. The 
International Forum for Logotherapy, 31(1), 55-56. 
 
Nassar, S. L. (2007). Movies of interest to logotherapists. The International Forum for 
Logotherapy, 30(2), 112-115. 
 
Nassar, S. L. (2007). A measure of interest to logotherapy researchers: The Humor Styles 
Questionnaire. The International Forum for Logotherapy, 30(1), 48-50. 
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Nassar, S. L. (2006). A measure of interest to logotherapy researchers: The Love Attitudes Scale. 
The International Forum for Logotherapy, 29(2), 119-121. 
 
Schulenberg, S. E., & Nassar, S. L. (2006, April 5). Meaningful cinema: Logotherapy and 
Finding Neverland [Review of the motion picture Finding Neverland].  
PsycCRITIQUES-Contemporary Psychology: APA Review of Books, 51 (No. 14), 
Article 17. Retrieved April 5, 2006, from the PsycCRITIQUES database. 
 
 
Presentations 
Nassar, S. L. (2012, December). Acceptance and Commitment Therapy: An experiential walk 
around the Hexaflex. Invited talk presented at Vanderbilt University, Nashville, TN. 
 
Gustafson, S. A., & Nassar, S. L. (2012, October). Time Series Design in Clinical 
Neuropsychophysiology. Invited lecture presented at the University of Alabama, 
Tuscaloosa, AL. 
 
Nassar, S. L., Wilson, K. G., Kellum. K. K. (2012, July). Defusion as a core ACT process: 
Conceptual definitions, current empirical literature, and future directions for 
exploration. In H. Bolderston (Chair), Cognitive fusion: Conceptualization and 
empirical findings. Symposium presented at the 10th Annual World Conference of the 
Association for Contextual Behavioral Science, Washington, D.C. 
 
Nassar, S. L., Conklin, H., M., Ashford, J. M., Zhou, Y., Cheng, C., Reddick, W. E., Glass, J. O., 
Jeha, S., & Pui, C-H. (2012, April). Cognitive Outcomes in Children Experiencing 
Seizures during Treatment for Acute Lymphoblastic Leukemia. In K. Tercyak & C. J. 
Heckman (Chairs), Pediatric Oncology: Survivorship and Prevention. Paper session 
presented at the 33rd Annual Meeting & Scientific Sessions of the Society of 
Behavioral Medicine, New Orleans, LA. 
 
Nassar, S. L. & Wilson, K. G. (2011, June). Adapting the Expressive Writing Paradigm as a 
Values-Based Intervention. In S. L. Nassar (Chair), New Directions in Values 
Assessment and Intervention. Symposium presented at the 9th Annual World 
Conference of the Association for Contextual Behavioral Science, Parma, Italy. 
 
Parman, M., Nassar, S. L., Kellum, K. K., & Wilson, K. G. (2011, May). Adapting the 
Expressive Writing Paradigm as a Values-Based Intervention. In A. Branstetter-Rost 
(Chair), The Potential Utility of Expressive Writing in Acceptance and Commitment 
Therapy: Moving Behavior in Valued Directions. Symposium presented at the 37th 
Annual Convention for the Association for Behavior Analysis International, Denver, 
CO. 
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Nassar, S. L., Wilson, K. G., & Kellum, K. K. (2010, June). Update on Values-Centered 
Adaption of the Expressive Writing Paradigm. In S. L. Nassar (Chair), Research and 
Therapeutic Application in the Context of Valued Living. Symposium presented at the 
8th Annual World Conference of the Association for Contextual Behavioral Science, 
Reno, NV. 
 
Flynn, M. K., Wilson, K. G., & Kellum, K. K., Nassar, S. L., Slater, R. M., Lucas, N. N., 
Bordieri, M., Bethay, S., Kolivas, E., & Kirkland, K. (June, 2010). Exploring the Use 
of the Hexaflex Functional Dimensional Experiential Interview. Paper presented at the 
8th Annual World Conference of the Association for Contextual Behavioral Science, 
Reno, NV. 
Nassar, S. L., Wilson, K. G., & Kellum, K. K. (2010, May). Update on Values-Centered 
Adaption of the Expressive Writing Paradigm. In S. L. Nassar (Chair), Research and 
Application in the Context of Valued Living. Symposium presented at the 36th Annual 
Convention for the Association for Behavior Analysis International, San Antonio, TX. 
 
Flynn, M. K., Wilson, K. G. Kellum, K. K., Nassar, S. L., Slater, R. M., Lucas, N., Bordieri, M., 
Bethay, S. (2010, May). Exploring the Use of the Hexaflex Functional Dimensional 
Experiential Interview. In S. L. Nassar (Chair), Research and Application in the 
Context of Valued Living. Symposium presented at the 36th Annual Convention for the 
Association for Behavior Analysis International, San Antonio, TX. 
 
Williamson, S., Nassar, S. L., & Johnson, C. (2009, October). Elementary and Middle School 
Interventions. In E. T. Johnson (Chair), Tutorial: Clinical Strategies within the 
Classroom for Children with Autism. Symposium presented at the 60th Annual 
Conference of the Mississippi Psychological Association, Gulfport, MS. 
 
Nassar, S. L., Flynn, M. K., Slater, R. M., Kellum, K. K., & Wilson, K. G. (2009, June). Values-
Centered Interventions. In R. M. Slater (Chair), Values in Acceptance and Commitment 
Therapy: Conceptualization, Clinical Exercises, and Assessment. Symposium 
presented at the Third Annual World Conference of the Association for Contextual 
Behavioral Science, Enschede, The Netherlands. 
 
Slater, R. M., Nassar S. L., Flynn, M. K., Kellum, K. K., & Wilson, K. G. (2009, June). What are 
Values? Unpacking Values as Conceptualized in Acceptance and Commitment 
Therapy. In R. M. Slater (Chair), Values in Acceptance and Commitment Therapy: 
Conceptualization, Clinical Exercises, and Assessment. Symposium presented at the 
Third Annual World Conference of the Association for Contextual Behavioral Science, 
Enschede, The Netherlands. 
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Flynn, M. K., Nassar, S. L., Slater, R. M., Kellum, K. K., & Wilson, K. G. (2009, June). An 
Improved Measure of Valued Living: The Valued Living Questionnaire-II (VLQ-2). In 
R. M. Slater (Chair), Values in Acceptance and Commitment Therapy: 
Conceptualization, Clinical Exercises, and Assessment. Symposium presented at the 
Third Annual World Conference of the Association for Contextual Behavioral Science, 
Enschede, The Netherlands. 
 
Nassar, S. L., Wilson, K. G., Kellum, K. K., & Sandoz, E. K. (2009, May). Mindfulness for Two 
(Part II): The Effects of Therapist Disclosure. In J. Weinstein (Chair), Mindfulness for 
Two (Part II): Manipulating the Therapist. Symposium presented at the 35th Annual 
Convention of the Association for Behavior Analysis International, Phoenix, AZ. 
 
Nassar, S. L., Wilson, K. G., Kellum, K. K., & Flynn, M. K. (2009, May). Values-Centered 
Writing: Explorations Within The Expressive Writing Paradigm. In S. L. Nassar 
(Chair), Research and Treatment in the Context of Valued Living. Symposium 
presented at the 35th Annual Convention of the Association for Behavior Analysis 
International, Phoenix, AZ. 
 
Howard, R. C., Nassar, S. L., Martin, L., Slater, R. M., Sandoz, E. K., Kellum, K. K., & Wilson, 
K. G. (2009, May). The Permanent Solution: Suicidal Behavior and Experiential 
Avoidance. In R. M. Slater (Chair), Psychological Flexibility and Difficult Clinical 
Presentations. Symposium presented at the 35th Annual Convention of the Association 
for Behavior Analysis International, Phoenix, AZ. 
 
Davis, D., Hamblin, B., Hankton, U. N., Nassar, S. L., Ofili, P., Weinstein, J., & Johnson, L. R. 
(2009, April). Updates on Outreach: Expanding Cultural Competence in our Services 
and Ourselves. Diversity Colloquium presented at the University of Mississippi, 
University, MS. 
 
Nassar, S., Tucker, C., & Ambrose, C. (June, 2008). Workplace Violence. Presentation given at 
the  Medical Ethics Committee meeting at North Mississippi Medical Center, Tupelo, 
MS. 
 
Nassar, S. L., Drake, C., & Wilson, K. G. (2008, May). One More Time: An Examination of the 
Stability of IRAP Performance over Repeated Administrations. In S. L. Nassar (Chair), 
How Words Measure Up: An Investigation of the Reliability, Validity, and Procedural 
Integrity of the Implicit Relational Assessment Procedure. Symposium presented at the 
34th Annual Convention of the Association for Behavior Analysis International, 
Chicago, IL. 
 
Bethay, S., Wilson, K. G., Lucas, N., Moyer, K., & Nassar, S. L. (2008, May). Acceptance and 
Commitment Training (ACT) to address burnout in staff caring for clients with 
intellectual disabilities (ID). In R. Slater (Chair), ACT Outside the Clinic: Application 
of Acceptance and Commitment Therapy to Non-clinical Populations. Symposium 
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presented at the 34th Annual Convention of the Association for Behavior Analysis 
International, Chicago, IL. 
Hankton, U. N., Hirschel, M., Nassar, S. L., Tracy, J., & Johnson, L. R. (2007, May). Reaching 
Out to International Students: Some Strategies and Lessons Learned. Diversity 
Colloquium presented at the University of Mississippi, University, MS. 
 
 
Posters 
Gustafson, S. A., Nassar, S. L., Waddell, D. E. (2012, April). Treatment of Neurally Mediated 
Syncope Using Spectral EEG Neurotherapy: A Single Case Design. Poster presented at 
the 33rd Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine, 
New Orleans, LA. 
 
Howard, R. C., Slater, R., Sandoz, E. K., Nassar, S. L., & Wilson, K. G. (2008, May). The 
Permanent Solution: Parasuicidality and Experiential Avoidance. Poster presented at 
the 34th Annual Convention of the Association for Behavior Analysis International, 
Chicago, IL. 
 
Nassar, S. L., & Hager, L. D. (2004, May). The Effects of Personality Type on Procrastination in 
College Students. Poster presented at Spring Hill College, Mobile, AL. 
 
 
Interviews 
Morris, M. G. (2008, February 1). Sweat out the small stuff … or not: Intense exercise, gentle 
meditative movement play key role in beating back unhealthy stress. Daily Journal, pp. 
1C, 3C. 
 
Morris, M. G. (2007, September 28). Putting the pieces back together: Young adults in transition 
particularly vulnerable to mental health issues. Daily Journal, pp. 1C, 6C. 
 
 
Workshops 
Nassar, S. L., & Waxenberg, L. B. (2014, May). Introduction to Acceptance and Commitment 
Therapy (ACT): An Interactive Workshop. Case Conference Series presented at the 
University of Florida College of Public Health and Health Professions, Department of 
Clinical and Health Psychology, Gainesville, FL. 
 
Wilson, K. G., Flynn, M. K., Bordieri, M. J., Slater, R. M., Nassar, S. L., Whiteman, K., & 
Schnetzer, L. W. (July, 2011). Treating Addiction with Co-Occurring Anxiety and 
Depression. Workshop presented at the 9th Annual Conference of the Association for 
Contextual Behavioral Science, Parma, Italy. 
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Wilson, K. G., Schnetzer, L. W., Flynn, M. K., Bordieri, M. J., Nassar, S. L., & Whiteman, K.  
(July, 2011).  Mindfulness and Values Interviewing in Acceptance and Commitment 
Therapy. Workshop presented at the 9th Annual Conference of the Association for 
Contextual Behavioral Science, Parma, Italy. 
 
Wilson, K. G., Sandoz, E. K., Flynn, M. K., Slater, R. M., Lucas, N. N., & Nassar, S. L. (June, 
2009). Learning Hexaflex Processes Using Mindfulness for Two Videos. Workshop 
presented at the Third Annual Conference of the Association for Contextual Behavioral 
Science, Enschede, Netherlands. 
 
Sandoz, E. K., & Nassar, S. L. (June, 2009). Know Thyself, Choose Thyself: Exploring Flexibility 
with Self and Valued Living. Workshop presented at the Third Annual World 
Conference of the Association for Contextual Behavioral Science, Enschede, The 
Netherlands. 
 
Wilson, K. G., Sandoz, E. K., Nassar, S. L., Lucas, N., Slater, R. M., Martin, L. (May, 2008). 
Advanced Experiential Case Conceptualization Workshop. Workshop presented at the 
4th Association for Contextual Behavioral Science Summer Institute, Chicago, IL. 
 
Nassar, S. L., Melton, A. M., & Schulenberg, S. E. (2006). Life Purpose Workshop. Workshop 
presented at the Psychological Services Center, University, MS. 
 
 
Editorial Positions 
 Guest Reviewer for Behaviour Research and Therapy (2013) 
 
 
Membership in Professional Associations 
     Society of Behavioral Medicine, Student Member, 2012 
     Mississippi Psychological Association, Student Affiliate, 2009 
     Gamma Beta Phi Society, Student Member, 2008 
     Association for Behavior Analysis, Student Affiliate, 2008 
     American Psychological Association, Student Affiliate, 2007 
     Association for Contextual Behavioral Science, Charter Member, 2006 
     Alpha Sigma Nu, Jesuit Honor Society, Student Member, 2004 
     Psi Chi, National Honor Society in Psychology, Student Member, 2002 
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Honors and Awards 
     2009 Wolfe Award Nominee 
     2009 Cambridge Who’s Who Honors 
     2008 Gamma Beta Phi Society 
     2008-2004 Graduate Honors Fellowship 
     2004 Alpha Sigma Nu 
     2004-1999 SouthTrust Bank Corporate Scholarship 
     2004-1999 Spring Hill College Faculty Honors Scholarship 
     2004-1999 Mobile Metropolitan Service Award 
     2004-1999 Dean’s List, Spring Hill College 
     2002 Psi Chi 
     2002 Outstanding Tutor of the Foley Community Service Center 
 
 
Professional Recommendations 
Kelly G. Wilson, Ph.D.    Robert T. Guenther, Ph.D., ABPP (RP) 
Professor, Director of UM Center for  Clinical Professor, Director of 
Contextual Psychology    Inpatient Consultation and Liaison Services 
Department of Psychology   Department of Clinical & Health Psychology 
205 Peabody Hall     University of Florida, Health Science Center 
University of Mississippi    PO Box 100165 
University, MS 38677    Gainesville, FL 32610 
662-816-5189     352-273-5268 
kwilson@olemiss.edu    rguenthe@phhp.ufl.edu 
 
 
 
Lori B. Waxenberg, Ph.D., ABPP    Scott A. Gustafson, Ph.D., ABPP 
Clinical Professor      Director, Psychological Services Center 
Director of Internship Training    Assistant Professor 
Department of Clinical & Health Psychology  Suite G-392 Kinard Hall  
University of Florida, Health Science Center  University of Mississippi 
PO Box 100165, Gainesville, FL 32610   University, MS 38677 
352-273-5273      662-915-5272 
lwaxenbe@phhp.ufl.edu     sagustaf@olemiss.edu 
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